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Abstract
New	players	are	emerging	in	the	game	of	peripheral	and	central	nervous	system	injury	since	their	physiopathological	mechanisms	remain	partially	elusive.	These	mechanisms	are	characterized	by	several	molecules
whose	 activation	 and/or	modification	 following	 a	 trauma	 is	 often	 controlled	 at	 transcriptional	 level.	 In	 this	 scenario,	microRNAs	 (miRNAs/miRs)	 have	 been	 identified	 as	main	 actors	 in	 coordinating	 important	molecular
pathways	in	nerve	or	spinal	cord	injury	(SCI).	miRNAs	are	small	non-coding	RNAs	whose	functionality	at	network	level	is	now	emerging	as	a	new	level	of	complexity.	Indeed	they	can	act	as	an	organized	network	to	provide	a
precise	control	of	several	biological	processes.	Here	we	describe	the	functional	synergy	of	some	miRNAs	in	case	of	SCI	and	peripheral	damage.	In	particular	we	show	how	several	small	RNAs	can	cooperate	in	influencing
simultaneously	the	molecular	pathways	orchestrating	axon	regeneration,	inflammation,	apoptosis	and	remyelination.	We	report	about	the	networks	for	which	miRNA-target	bindings	have	been	experimentally	demonstrated	or
inferred	based	on	target	prediction	data:	in	both	cases,	the	connection	between	one	miRNA	and	its	downstream	pathway	is	derived	from	a	validated	observation	or	is	predicted	from	the	literature.	Hence,	we	discuss	the
importance	of	miRNAs	in	some	pathological	processes	focusing	on	their	functional	structure	as	participating	in	a	cooperative	and/or	convergence	network.
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1	PERIPHERAL	AND	CENTRAL	AXON	DEGENERATION	AFTER	INJURYeripheral	and	central	axon	degeneration	after
injury
Peripheral	and	central	injury	(due	to	motor	vehicle	accident,	falls	or	sporting	injuries)	may	severely	damage	axons	and/or	neurons,	leading	to	a	partial	or	complete	motor,	sensory	and/or	autonomic	dysfunction,	and	considerably
compromising	 the	 patient	 quality	 of	 life.	 Depending	 on	 the	 injury	 severity,	 neural	 death,	 inflammation	 and	 retrograde	 degeneration	 occur	 at	 different	 extent	 as	 consequence	 of	 specific	molecular	 degenerative	mechanisms.	We
summarize	the	key	events	and	pathways	taking	place	upon	PNS/CNS	damage	and	leading	to	degeneration.
As	concerns	PNS,	during	the	first	phases	after	injury,	axon	and	myelin	damage	occurs	both	at	the	proximal	and	distal	segments	of	the	nerve	in	a	process	called	Wallerian	degeneration.	In	the	first	hours	after	the	injury	the	end
of	the	axon	swells	and	in	two	days	the	increase	of	intracellular	Ca2+	induces	axon	degeneration	through	calcium	dependent	proteolytic	enzymes	such	as	calpain	(George	et	al.,	1995).	The	increased	Ca2+	influx	leads	to	kinase	activation
such	as	dual	leucine	zipper	kinase,	c-Jun	N-terminal	kinase	(JNK),	inhibitor	of	kappa	kinase	complex	(IKK)	and	glycogen	synthase	kinase	3	(GSK-3)	whose	inhibition	protect	axons	in	dorsal	root	ganglion	(DRG)	neuron	culture	(Gerdts	et
al.,	 2011;	Michaelevski	 et	 al.,	 2010).	Pathways	 involving	 transforming	growth	 factor-β	(TGF-β)/mothers	 against	 decapentaplegic	 homolog	 2/3(SMAD2/SMAD3)	 and	 sterile	 alpha-	 and	 armadillo-motif-containing	 protein-1	 have	 been
identified	as	negative	signals	limiting	axonal	ability	to	regrowth	(Gerdts	et	al.,	2013;	Patent	number	US7524640B2).
The	growth	pathway	involving	phosphoinositide	3-kinases-protein	kinase	B	(PI3K-AKT),	whose	inhibition	is	associated	with	poor	growth	ability,	is	repressed	by	phosphatase	and	tensin	homolog	(PTEN)	after	peripheral	nerve
injury.	Indeed	its	in	vivo	inhibition	in	a	rat	sciatic	nerve	injury	model	accelerates	axon	outgrowth	(Christie	et	al.,	2010).	Despite	the	molecular	signals	inhibiting	regeneration,	the	axons	of	a	peripheral	nerve	show	an	intrinsic	growth
capacity.	Within	hours	from	injury,	genes	with	regenerative	capabilities	are	activated:	JUN,	FOS,	activating	transcription	factor	3	(ATF3)	and	cAMP	response	element	binding	protein	(CREB).	CREB3	knock	out	(KO)	in	DRG	culture
significantly	reduces	neurite	elongation,	demonstrating	its	fundamental	role	after	injury	(Ying	et	al.,	2014).	Locally	released	cytokines,	such	as	leukemia	inhibitory	factor	(LIF)	and	interleukin-6	(IL-6),	activate	the	downstream	growth
associated	protein	43	(GAP-43)	after	DRG	peripheral	injury	(Cafferty	et	al.,	2004).	GAP-43	is	the	first	recombination	activating	gene	originally	discovered	by	Skene	and	Willard	(1981),	whose	induction	after	sciatic	nerve	injury	strongly
correlates	with	regeneration	(Skene	and	Willard,	1981).	LIF	also	activates	the	Janus	kinase	2-signal	transducer	and	activator	of	transcription	3	(JAK2-STAT3)	pathway	in	DRG	neurons:	STAT3	is	specifically	associated	to	the	early	phase
of	axon	regeneration	in	PNS	(Bareyre	et	al.,	2011).
While	axon	degeneration/regeneration	occur,	T	cells,	neutrophils	and	macrophages	infiltrate	the	injury	site,	increasing	the	level	of	early	inflammatory	cytokines,	tumor	necrosis	factor	alpha	(TNF-α)	and	interleukin-1α	(IL-1α)
(Wagner	and	Myers,	1996).	In	the	following	days	the	inflammatory	reaction	is	amplified	by	macrophages,	mast	cell	recruitment	and	endothelial	cell	activation.	Macrophages	remove	myelin	debris	and	myelin	associated	molecules	(like
myelin-associated	glycoprotein,	MAG)	that	inhibit	regeneration	(Baichwal	et	al.,	1988;	da	Costa	et	al.,	1997).	Resident	macrophages	(4%	of	the	total	number)	rapidly	respond	to	the	injury	and	then	circulating	macrophages	(chemokine
c-–c	motif	receptor	2)	are	recruited	to	the	lesion	side	where	they	constitute	the	main	cell	components	of	the	bridge	for	the	new	growing	tissue	(Siebert	et	al.,	2000).	Moreover	they	are	also	recruited	by	chemokine	(c-–c	motif	ligand	2)
secreted	by	SCs	that	is	fundamental	in	regulating	the	axonal	regrowth	program	via	LIF/STAT3	mechanism.	Notably,	two	distinct	populations	of	macrophages	are	described:	M1	with	a	proinflammatory	function	and	M2	working	in	the
opposite	direction	(Ydens	et	al.,	2012).
SCs	after	injury	break	off	from	the	damaged	axons,	dedifferentiate,	secrete	cytokines	and	promote	immune	cell	infiltration.	JUN	is	the	main	factor	responsible	for	the	initial	transition	from	myelinating	to	non-myelinating	SCs
that	allow	a	complete	clearing	of	the	tissue	for	a	successful	regeneration.	This	is	consistent	with	the	downregulation	of	myelin	genes	(MBP,	MAG	and	peripheral	myelin	protein	22-PMP-22)	and	the	upregulation	of	immature	SC	markers
such	as	neural	 cell	 adhesion	molecule	 (NCAM),	p75	neurotrophin	 receptor	and	glial	 fibrillary	acidic	protein	 (GFAP)	 (Chen	et	al.,	 2007;	 Jessen	and	Mirsky,	2008).	On	 the	 other	hand,	 a	 set	 of	 trophic	 factors	 inactive	 in	normal	 or
developing	SCs	 [for	 instance	glial	cell	 line-derived	neurotrophic	 factor,	artemin,	brain-derived	neurotrophic	 factor	 (BDNF)	and	nerve	growth	 factor	 (NGF)	 (Boyd	and	Gordon,	2003)]	appear.	 In	addition,	 the	products	of	early	axon
degeneration	stimulate	SCs	to	remove	myelin	debris	and	recruit	macrophages	by	the	toll-like	receptors	nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells.	Due	to	the	separation	from	the	axons,	SCs	synthetize	TNF-α,	IL-1α
and	interleukin	β	that	in	turn	contribute	to	monocyte	and	macrophages	attraction	and	infiltration	(Shamash	et	al.,	2002).	Additionally,	starting	from	4	days	after	trauma,	denervated	SCs	divide	both	at	the	proximal	and	distal	stumps	of
the	lesioned	axon	(Mitchell	et	al.,	1990;	Trapp	et	al.,	1988).	If	regenerating	axons	are	re-contacted	by	SCs,	they	can	unwrap	it	by	myelin	sheet,	otherwise	they	undergo	apoptosis.
If	 the	balance	between	regenerative/degenerative	program	is	high,	a	successful	nerve	regeneration	can	occur.	However	 the	regenerative	capabilities	of	 the	PNS,	albeit	considerable,	are	often	not	sufficient	 to	guarantee	a
complete	reinnervation	and	functional	recovery:	 if	a	disorganized	axon	sprouting	occurs,	the	circuitry	refinement	maybe	inadequate,	resulting	in	sensory	deficit	and	limited	motor	control	 (Battiston	et	al.,	2009;	Wu	and	Murashov,
2013).
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Contrarily	 to	 the	 PNS,	 after	 a	 CNS	 lesion,	 the	 spinal	 cord	 has	 a	 very	 limited	 capability	 to	 restore	 its	 connectivity.	 This	 poor	 ability	 is	 due	 both	 to	 a	 sequence	 of	 anatomical	 changes	 (including	 neuron	 cell	 death,
neuroinflammatory	reaction,	glial	scar	formation	and	myelin	inhibitory	proteins)	that	create	a	growth	inhibitory	environment,	and	to	the	adult	physiological	inactivation	of	the	growth	program	by	oligodendrocytes	(OLs)	(Kwon	et	al.,
2004).	The	time	course	of	the	post	injury	modifications	is	characterized	by	an	initial	phase	(0–2	h)	of	neuronal	and	glial	death	associated	with	hemorrhage	and	ischemia	both	rostrally	and	caudally	to	the	lesion,	followed	by	an	acute
phase	 (2h-2	weeks)	 that	 consists	 of	 an	 intense	 inflammation	process	 (microglia,	 astrocyte,	neutrophil	 and	T	 cell	 recruitment)	 resulting	 in	 the	glial	 scar	 formation,	neurotoxicity	 and	 further	 cell	 death	and	demyelination.	Then	an
intermediate	phase	characterized	by	glial	scar	maturation	and	inefficient	attempts	of	axon	sprouting	occurs	(2	weeks-6	months).	In	the	last	chronic	phase	(>	6	months)	the	 lesion	stabilizes:	glial	scar	continuously	 forms,	Wallerian
degeneration	occurs	and	axon	fragmentation	leads	to	final	deficits	and	symptoms.
More	 in	detail	neuron	and	OL	death	 is	 the	 first	event,	occurring	earlier	by	necrosis	and	 later	by	apoptosis.	As	 for	PNS,	 the	Ca2+	 influx	 induced	by	 the	 lesion	 leads	 to	calpain	activation	with	mitochondria	dysfunction	and
excitotoxicity	damage	(mediated	by	N-methyl-DD-aspartate	receptor).	Reactive	oxygen	and	nitrogen	species	exacerbate	the	damage	causing	OL	loss	that	in	turn	leads	to	further	neural	cell	death.	One	of	the	first	apoptotic	pathways
activated	is	the	JNK	cascade,	whose	specific	inhibition	prevents	caspase	3	cleavage,	promotes	locomotor	recovery	and	neuroprotection	after	SCI	(Repici	et	al.,	2012).	Upstream	caspase	activation,	associated	protein	with	death	domain-
associated	protein	with	death	domain	ligand	(FAS-FAS-L)	mediated	cascade	plays	a	critical	role	in	axon	degeneration	and	OL	apoptosis:	FAS	deficient-mice	with	a	SCI	compression	show	improved	locomotor	recovery,	axonal	sparing
and	myelin	preservation	(Casha	et	al.,	2005;	Yu	et	al.,	2009).
The	limited	regrowth	ability	of	CNS	is	probably	due	to	the	lack	of	a	sustained	upregulation	of	growth	factors.	However	it	is	known	that	when	BDNF,	neurotrophin	3,	4	and	ciliary	neurotrophic	factor	are	released	at	the	spinal
lesion	level,	they	are	able	to	sustain	axon	growth	after	1-–2	months	from	the	injury	(Bregman	et	al.,	2002).	Similarly,	 the	selective	downregulation	of	axon	growth	inhibitory	molecules,	such	as	Ras	homolog	gene	family	member	A
(RhoA),	GSK-3β	and	PTEN,	strongly	sustains	axon	regeneration.	Synaptogenesis	and	neurite	outgrowth	are	reached	by	a	RhoA	inhibitory	treatment	in	a	rat	acute	SCI	model	(Devaux	et	al.,	2017);	GSK-3β	inhibition	significantly	reduces
secondary	damage	of	SCI	and	ameliorates	motor	recovery	in	injured	mice	(Cuzzocrea	et	al.,	2006);	conditional	PTEN	depletion	enhances	the	regenerative	growth	of	corticospinal	tract	in	association	with	motor	function	restoration	in
adult	mice	post-SCI	(Danilov	and	Steward,	2015).	Other	growth	inhibitors	belong	to	1)	chemorepulsive	axon	guidance	molecules,	such	as	the	semaphorin	family	known	to	be	expressed	after	SCI,	or	ephrin,	netrin	and	wingless-related
integration	site	(wnt)	known	to	limit	axonal	elongation	in	CNS	lesion;	2)	chondroitin	sulfate	proteoglycans	(like	neurocan,	brevican,	versican),	a	class	of	extracellular	matrix	molecules	that	are	expressed	by	astrocytes	in	the	glial	scar
and	therefore	limit	neuronal	plasticity.	In	addition,	neurite	outgrowth	inhibitors,	MAG	and	OLs	myelin	glycoprotein	synergistically	restrict	axon	growth	after	SCI	(Cafferty	et	al.,	2010).
Neural	death	and	axon	regeneration	proceed	in	parallel	to	a	demyelinating	process	that	is	quite	different	from	the	processes	activated	in	the	peripheral	system.	In	detail,	demyelination	is	accompanied	by	oligodendrocytes
progenitor	cell	(OPC)	proliferation	as	demonstrated	by	the	presence	of	neural/glial	antigen	2	positive	cells	4	weeks	after	SCI	and	increased	level	of	fibroblast	growth	factor-2	(FGF-2),	a	mitotic	factor	that	maintains	OPC	renewal	state
(McTigue	et	al.,	2001;	Mocchetti	et	al.,	1996).	However	OPC	maturation	and	remyelination	 is	prevented	by	the	Notch1	expression	rostral	and	caudal	to	the	 injury	(Chen	et	al.,	2005):	 indeed	Notch	signals,	with	“a	disintegrin	and
metalloprotease”	(ADAM)	molecules	as	downstream	effectors,	block	myelin	maturation.	Also	NCAM,	a	factor	that	prevents	myelination,	increases	in	dorsal	spinal	cord,	motor	neurons	and	corticospinal	tract	after	SCI	transection	(Tzeng
et	al.,	2001).
The	apoptosis	of	neurons	and	oligodendrocytes	(OLs)	is	also	the	result	of	the	inflammatory	response.	Vessels	and	blood	brain	barrier	breakdown	cause	a	rapid	infiltration	of	neutrophils	and	T	cells,	attracted	by	an	initial	release
of	TNF-α	and	IL-6	(Habgood	et	al.,	2007;	Pineau	and	Lacroix,	2007).	The	following	increased	production	of	cytokines	gives	rise	to	the	secondary	inflammatory	response	characterized	by	macrophage	and	microglia	recruitment.	The
inflammation	molecular	mediators	 (as	TNF-α)	are	generally	described	to	have	a	dual	role,	neurotoxic	or	neuroprotective	 (Kim	et	al.,	2001;	Lavine	et	al.,	1998).	A	similar	 role	 is	attributed	 to	microglia	 that	after	an	 injury	become
activated	 assuming	 a	 typical	 amoeboid	 structure:	 microglia	 depletion	 can	 be	 neuroprotective,	 but	 its	 controlled	 activation	 can	 also	 be	 beneficial.	 This	 paradox	 is	 explained	 by	 the	 presence	 of	 two	 different	 classes	 of	 cells,
proinflammatory	M1	and	anti-inflammatory	M2	microglial	cells	(Kigerl	et	al.,	2009).
Also	astrocytes	are	activated	by	injury:	these	cells	form	a	strong	inhibitory	scar	that	works	as	an	anatomical	barrier	for	axonal	regeneration,	in	the	ineffective	attempt	to	limit	the	spread	of	damage	and	preserve	the	healthy
tissue.	Astrocytes	are	recruited	to	the	injury	site	by	a	molecular	cascade	that	includes	TGF-β,	interleukin-1	(IL-1),	interferon-γ	and	FGF-2,	and	become	hypertrophic	with	an	increased	production	of	GFAP	(Cregg	et	al.,	2014).
However,	despite	the	limited	axon	regrowth	potential	of	CNS,	some	regeneration	associated	genes	have	been	described	after	central	lesion.	For	example,	the	transcription	factor	CREB	is	induced	by	SCI	and	is	able	to	promote
axon	growth	and	regeneration	when	overexpressed	(Qiao	and	Vizzard,	2005;	Qiu	et	al.,	2002).	The	transcription	factor	ATF3	is	known	to	enhances	c-Jun	mediated	sprouting	in	response	to	neural	axotomy	in	vitro	(Pearson	et	al.,	2003).
JAK-STAT	pathway	is	described	to	control	the	reestablishment	of	spinal	cord	continuity	in	response	to	a	Xenopus	Laevis	model	of	spinal	cord	injury	with	a	differential	pathway	activation	during	regenerative	and	non-regenerative	stages
(Tapia	et	al.,	2017).	GAP-43	can	promote	axon	growth	when	upregulated	after	SCI	compression	(Curtis	et	al.,	1993;	Zhang	et	al.,	2005).
Therefore	 the	 contribution	 of	 several	 different	 pathways	 for	 PNS-CNS	 response	 to	 injury	 is	 quite	 evident	 and	 extremely	 tangled.	However	 the	 level	 of	 complexity	 increases	 considering	microRNA	 (miRNAs/miRs)	 as	 new
upstream	regulators	that,	acting	as	networks,	control	simultaneously	different	processes.
2	ORIGIN,	BIOGENESIS	AND	NOMENCLATURE	OF	MICRORNArigin,	biogenesis	and	nomenclature	of	micrornas
MiRNAs	are	small	non-coding	RNAs	about	20-–22	nucleotides-long,	which	negatively	regulate	gene	expression	at	post-transcriptional	level.	They	were	discovered	by	Lee	et	al.	(1993),	who	demonstrated	that	lin-4	“gene”	is	able
to	repress	the	lin-14	gene	(Lee	et	al.,	1993).	Only	in	early	2000s,	lin-4	and	let-7	(the	second	to	be	characterized)	were	described	as	part	of	a	large	group	of	RNAs	present	in	several	organisms	(from	C.	elegans	to	humans)	and	involved
in	 different	 biological	 processes	 (Lagos-Quintana	 et	 al.,	 2001;	 Lau	 et	 al.,	 2001;	 Lee	 and	Ambros,	 2001;	 Lim	 et	 al.,	 2003a,	 2003b;	 Pasquinelli	 et	 al.,	 2000).	 Soon	 after	miRNAs	were	 also	 found	 in	 plants	 suggesting	 that	 they	 are
evolutionary	conserved	(Dugas	and	Bartel,	2004;	Reinhart,	2002).	Since	then,	research	on	miRNAs	expanded	rapidly,	demonstrating	not	only	how	many	different	physiological	roles	they	play,	but	also	revealing	how	their	aberrant
expression	is	implicated	in	several	diseases.	MiRNAs	are	highly	conserved	across	species:	they	appeared	first	in	invertebrates	as	a	defense	mechanism	against	infection,	then	were	conserved	through	evolution	to	refine	gene	expression
in	more	complex	organisms	(Lee	and	Ambros,	2001).	At	present,	over	2000	miRNAs	have	been	involved	in	the	regulation	of	one	third	of	the	human	genes	(Hammond,	2015).	These	small	RNAs	are	spread	in	the	genome	and	can	be
transcribed	either	as	independent	units	or	as	located	within	the	intron	or	an	untranslated	region	of	a	coding	gene	(Lim	et	al.,	2003a).	Moreover,	50%	miRNAs	derive	from	a	unique	polycistronic	unit,	sharing	the	same	promoter	that
gives	raise	to	their	mature	forms	(Lee	et	al.,	2002;	Rodriguez	et	al.,	2004).	Polycistronic	miRNA	transcripts,	that	can	be	up	to	ten	kb	in	mammals,	are	organized	in	clusters.	A	cluster	is	defined	as	a	unit	in	which	miRNAs	are	closer	than
1	kb	between	each	other,	allowing	their	coordinated	transcription	and	function.	Similarly,	a	miRNA	family	is	defined	as	a	group	of	small	RNA	deriving	from	a	common	ancestor	that	generally	have	similar	physiological	functions	but	that
are	 not	 always	 conserved	 in	 primary	 sequence	 or	 secondary	 structure	 (Ambros	 et	 al.,	 2003;	 Griffiths-Jones	 et	 al.,	 2003;	 Kozomara	 and	 Griffiths-Jones,	 2014;	Wright	 and	 Bruford,	 2011).	 The	 cluster	 and	 the	 family	 organization
underscores	the	underestimated	complexity	of	the	miRNA	role.	The	miRNA	maturation	process	(Fig.	1)	can	be	divided	in	two	steps	(Bartel,	2004).	The	first	one	consists	of	miRNA	transcription	by	the	RNA	polymerase	II	into	the	primary
miRNA	(pri-miRNA)	(Lee	et	al.,	2004):	this	hairpin	loop	structure	undergoes	a	process	of	capping	(at	5’end),	polyadenylation	with	multiple	adenosine	(poly-A	tail)	and	splicing.	Then,	DiGeorge	Syndrome	critical	region	8	(DGCR8)-
Drosha	association	(Filippov	et	al.,	2000;	Han	et	al.,	2004)	is	required	for	the	cleavage	of	the	double-stranded	pri-miRNA,	thus	releasing	the	hairpin	and	allowing	the	formation	of	the	precursor	miRNA	(pre-miRNA)	(Ketting	et	al.,	2001;
Knight	and	Bass,	2001).
Additionally,	the	nuclear	factor	TAR	DNA-binding	protein	43	(TDP-43),	involved	in	neurodegenerative	diseases	like	amyotrophic	lateral	sclerosis	(ALS),	selectively	affects	miRNA	synthesis	pathway	(Buratti	et	al.,	2010)	as	an
accessory	component	that	directly	interacts	with	the	Drosha-DGCR8	complex	(Kawahara	and	Mieda-Sato,	2012).	Indeed	TDP-43	plays	a	crucial	role	in	the	stabilization	of	Drosha	protein	during	neural	differentiation	as	demonstrated	for
the	first	time	by	a	reduced	miRNA	production	in	human	TDP-43	KO	neuroblastoma	cell	line	(Di	Carlo	et	al.,	2013).	Moreover	miRNA-independent	gene-regulatory	function	of	miRNA	biogenesis	enzymes	have	been	demonstrated	to
control	different	CNS	processes	as	for	instance	Drosha	control	of	Neurogenin	2	(Neurog2)	and	neuronal	differentiation	1	(NeuroD1)	are	essential	for	neurogenesis	maintenance	(Knuckles	et	al.,	2012).	Indeed	TDP-43	activity	on	Drosha
stability	is	also	an	indirect	way	to	post-transcriptionally	regulate	Drosha	target,	Neurog2,	a	transcription	factor	(TF)	critical	for	neural	differentiation.	TDP-43	exerts	both	an	indirect	and	direct	control	on	Neurog2	mRNA,	that	in	turn
Fig.	1	miRNA	maturation	process.
alt-text:	Fig.	1
regulates	NeuroD1	expression	whose	production	is	again	modulated	by	Drosha.	The	final	effector	NeuroD1	induces	the	expression	of	genes	related	to	neural	differentiation.	Independently	from	Dicer	and	miRNA	biogenesis,	Drosha
also	 targets	 nuclear	 factor	 1	B	 preventing	 OL	 fate	 acquisition	 by	 neural	 precursors	 (Rolando	 et	 al.,	 2016).	 Not	 only	 Drosha	 but	 also	 DGCR8	 directly	 affects	 corticogenesis,	 as	 its	 deletion	 pushes	 a	 premature	 neural	 precursor
differentiation	and	an	increased	number	of	T-box	brain	1	positive	neurons	(Marinaro	et	al.,	2017).
Both	pri-	and	pre-miRNAs	can	be	modified	by	RNA-editing,	which	entails	important	functional	implications	related	to	maturation	and	target	specificity	(Blow	et	al.,	2006;	Kawahara	et	al.,	2008;	Yang	et	al.,	2006).	The	adenosine
deaminases	 are	 responsible	 for	 this	 process	 converting	 the	adenosine	of	 the	miRNA	stem	 region	 into	 inosine	 (Yang	et	al.,	2006).	Moreover	 some	additional	 proteins	 control	 both	pri-	 and	pre-miRNA	processing:	KH-type	 splicing
regulatory	proteins	and	LIN28	interact	with	the	terminal	loop	of	pri-	and	pre-miRNAs	facilitating	and	inhibiting	respectively	DROSHA	and	Dicer	activity	(Trabucchi	et	al.,	2009;	Viswanathan	et	al.,	2008)	Then	the	enzyme	exportin	5
translocates	the	generated	pre-miRNA	from	the	nucleus	to	the	cytoplasm,	where	the	second	step	occurs	(Kim,	2004).	Here,	the	endonuclease	Dicer,	in	association	with	trans-activation	response	RNA-binding	protein	(TRBP),	removes
the	 loop	 from	 the	5′	and	3′	 ends	producing	a	double	RNA	of	21-–22	nucleotides.	Usually	 only	 one	 strand	becomes	 the	 real	mature	miRNA,	while	 the	other	 is	 degraded	 (Khvorova	et	al.,	2003).	However,	 recently	 next	 generation
sequencing	experiments	demonstrated	that	occasionally	both	strands	could	be	expressed.	Therefore	i)	the	standard	nomenclature	system	named	“5p”	the	microRNAs	derived	from	the	5′	arm,	and	“3p”	those	derived	from	the	3′	arm	of
the	hairpin	stem	loop;	ii)	they	are	loaded	at	the	same	frequency	in	the	RNA-induced	silencing	complex	(RISC).	Additionally,	when	distinct	precursor	sequences	and	genomic	loci	express	identical	mature	sequences,	they	are	named	“1”
and	“2”,	as	for	example	miR-121-1	and	miR-121-2.	However	it	is	also	possible	to	find	“miR-121a”	and	“miR-121b”,	in	which	letter	suffixes	denote	closely	related	mature	sequences	deriving	from	two	different	precursors	(Kozomara	and
Griffiths-Jones,	 2014).	 The	 selected	 single	 strand/double	 strand(s)	 is/are	 incorporated	 in	 the	 RISC	 that,	 among	many	 other	 components,	 contains	 the	 Argonaute	 (AGO)	 proteins	 (Vaucheret	 et	 al.,	 2004)	 essential	 for	 the	 miRNA
orientation	and	interaction	with	their	targets	occurring	between	6-	and	8	nucleotides	(seed	region)	at	the	5′	UTR	of	the	miRNA	and	the	mRNA	3′	UTR.
The	maturation	process	described	above	is	the	most	frequent,	but	alternative	pathways	may	occur	for	some	miRNA	families	(Ha	and	Kim,	2014).	Drosha-independent	(but	still	Dicer	dependent)	pathways	have	been	described
for	mirtrons	(miRNA	located	in	mRNA	introns)	and	miRNAs	derived	from	short	hairpin	RNAs	(Okamura	et	al.,	2007;	Xie	et	al.,	2013):	in	the	first	case	pre-miRNA	is	generated	by	splicing,	debranching	and	trimming	processes,	while	in
the	second	the	miRNA	(for	example	miR-320)	is	directly	transcribed	and	transported	by	exportin	1.	Also	Dicer-independent	biogenesis	is	possible	as	in	the	case	of	miR-451,	that	is	directly	loaded	to	AGO2	protein	to	produce	the	miRNA
mature	transcript	(Cifuentes	et	al.,	2010;	Yang	et	al.,	2010).	Finally	some	miRNAs,	like	let-7	and	miR-105,	present	a	short	3′	overhang	from	Drosha	processing	that	requires	terminal	uridylyl	transferases	mono-uridylation	in	order	to	be
processed	by	Dicer	(Heo	et	al.,	2012).
At	 the	 same	 time,	miRNA	 cleavage/translational	 repression	 of	 the	 target	 represents	 their	 traditional	mechanism	 of	 action,	 but	 not	 the	 only	 one.	 Indeed,	 some	miRNAs,	 during	 cell	 quiescence,	may	 directly	mediate	 the
upregulation	of	their	targets	(Rusk,	2008).	The	apparently	intricated	miRNA	panorama	starts	from	their	biogenesis,	reflecting	how	wide	is	their	role	in	a	great	variety	of	biological	processes.	The	aim	of	this	review	is	to	provide	an
overview	of	the	complex	mechanisms	of	action	of	miRNAs	into	the	Nervous	System,	showing	in	particular	how	their	expression	changes	after	peripheral	nerve	and	spinal	cord	injury	(SCI).
3	MiRNAs	IN	PERIPHERAL	AND	CENTRAL	AXON	REGENERATIONin	peripheral	and	central	axon	regeneration
In	the	last	ten	years	the	increasing	interest	in	miRNAs	in	the	nervous	system	revealed	their	specific	involvement	in	many	aspects	of	neuronal	function	and	disease,	such	as	neurite	growth	and	neurodegeneration.	To	underline
the	potentially	big	impact	of	non-coding	RNAs	in	neurodegenerative	diseases,	the	latter	ones	are	often	defined	as	RNA	disorders	(Johnson	et	al.,	2012).	Moreover,	taking	into	account	miRNA	intrinsic	properties	to	regulate	several
biological	functions,	it	is	not	surprising	that	they	are	considered	one	of	the	major	players	in	the	pathogenesis	of	CNS/PNS	injury.
The	whole	PNS	regenerative	process	is	driven	by	a	sequence	of	cellular	and	molecular	mechanisms	and	involves	also	miRNAs,	as	demonstrated	by	recent	deep	sequencing	studies	revealing	an	abnormal	miRNA	expression	after
peripheral	nerve	injury	in	vivo	(Li	et	al.,	2012;	Yu	et	al.,	2011a).	Aiming	at	reestablishing	their	normal	expression,	a	series	of	studies	focused	on	the	modification	of	a	single	or	entire	miRNA	family.	For	instance,	the	inhibition	of	let-7
miRNA	both	in	vitro	(co-culture	of	SCs	and	DRG	neurons)	and	in	vivo	(nerve	transection	in	adult	male	rats)	increases	NGF	secretion	and	enhances	axonal	outgrowth	within	a	regenerative	microenvironment	(Li	et	al.,	2015).	Acting	on	a
different	pathway,	miR-26a	supports	mammalian	axon	regeneration	through	the	inhibition	of	GSK-3β	activity	in	a	model	of	adult	mouse	DRGs	and	sciatic	nerve	crush	(Jiang	et	al.,	2015).	The	same	small	RNA	also	promotes	neurite
outgrowth	in	vitro	via	the	suppression	of	PTEN	expression,	one	of	the	best	characterized	pathways	for	axonal	growth	(Cui	et	al.,	2015;	Li	and	Sun,	2013).	Another	important	player	in	regulating	axonal	growth	is	miR-21,	which	is
induced	after	DRG	in	vivo	axotomy	and	can	promote	regeneration	under	its	overexpression	(Strickland	et	al.,	2011b).	In	a	similar	model	(DRG	neuronal	culture	study)	both	miR-431	gain	of	function	and	knockdown	of	its	downstream
effector	Kremen	1	(wnt-βcatenin	canonical	pathway)	significantly	enhance	axon	outgrowth	(Wu	and	Murashov,	2013).	Therefore,	by	acting	on	the	same	and/or	different	pathways,	there	is	evidence	of	the	influence	of	miRNAs	in	the	field
of	peripheral	nerve	regeneration.	On	the	other	hand	in	the	CNS	context	in	which	sprouting	is	limited	and	axon	regeneration	almost	absent,	miRNAs	represent	major	players	in	the	maladaptive	changes	occurring	after	SCI.	As	for	the
PNS,	several	studies	analyzed	the	global	profiling	of	miRNA	expression	after	SCI	obtaining	differential	expression	for	a	great	number	of	small	RNAs	(Liu	et	al.,	2009).	Indeed	they	can	play	either	a	protective	or	a	detrimental	role
(Nieto-Diaz	et	al.,	2014;	Ning	et	al.,	2014).	Some	miRNAs	acting	on	different	pathways	promote	functional	recovery.	For	instance,	an	increased	axon	density	within	the	lesion	site	was	shown	after	miR-21	inhibition	in	astrocytes	in	a	SCI
mouse	model	(Bhalala	et	al.,	2012).	Even	better,	miR-133b	is	an	important	determinant	for	axon	regrowth	and	functional	recovery	by	reducing	RhoA	protein	in	an	adult	zebrafish	SCI	model	(Yu	et	al.,	2011b).	Considering	that	some
miRNAs	are	evolutionarily	conserved,	the	ability	of	let-7	to	turn	back	the	clock	on	regeneration	in	adult	C.	elegans	neurons	suggests	that	its	potential	could	also	be	applied	for	mammalian	axon	regrowth	(Nix	and	Bastiani,	2013;	Zou	et
al.,	2013).	Moreover	further	evidence	for	the	regenerative	potential	of	some	miRNAs	comes	from	in	vitro	studies,	such	as	the	role	exerted	on	embryonic	cortical	neurons	when	the	miR-17-92	cluster	is	overexpressed:	indeed	this	cluster
acts	on	PTEN	pathway	as	many	other	small	RNAs,	included	the	miR-29	family	(Zhang	et	al.,	2013;	Zou	et	al.,	2015a).	It	is	noteworthy	that	miR-17-92	and	STAT3	are	linked	in	a	positive	feedback	loop	in	which	STAT3	activation	is	related
to	an	overexpression	of	this	miRNA	cluster	in	retinoblastoma	cells	in	vitro	(Jo	et	al.,	2014):	although	such	connection	has	been	only	confirmed	in	cancer	pathways	so	far,	it	could	affect	also	the	axon	growth	pathways,	since	STAT3	is	a
crucial	TF	in	neurite	outgrowth	(Jo	et	al.,	2014).	Somewhere	in	between	peripheral	and	central	nervous	damage,	miR-142-3p	seems	to	be	a	potential	target	to	enhance	central	regeneration	of	primary	sensory	neurons	by	inhibiting	the
adenylyl	cyclase	9	molecule	(Wang	et	al.,	2015a).
The	list	of	miRNAs	with	regrowth	potential	is	long	in	the	literature	and,	despite	the	encouraging	results	achieved,	we	are	still	far	from	a	full	understanding	of	their	mechanisms.	The	main	reason	lies	in	the	difficulty	to	connect
every	single	element	to	reconstruct	a	broken	system.	This	is	particularly	true	for	miRNAs,	since	each	of	them	is	only	a	piece	of	a	complex	and	perfectly	functioning	puzzle.	For	this	reason	it	is	necessary	to	re-think	of	miRNAs	not	as
acting	singularly,	but	as	coordinated	members	of	different	groups.	Therefore	in	the	following	paragraphs,	we	will	show	some	examples	of	miRNA	actions,	demonstrating	their	synergistic	role	in	well-known	molecular	pathways	related
to	axonal	growth,	inflammation,	apoptosis	and	remyelination.	Even	though	CNS	and	PNS	differ	for	many	aspects,	we	try	to	describe	miRNAs	of	the	two	systems	in	the	same	pathway,	since	we	consider	that	some	possible	common
cascade	and/or	functions	maybe	reasonably	integrated.
4	MiRNAs	AND	TRANSCRIPTION	FACTORS	AS	REGULATORS	OF	AXON	GROWTH	AND	REGENERATIONand
transcription	factors	as	regulators	of	axon	growth	and	regeneration
As	previously	mentioned,	immediately	after	injury	there	is	a	large	increase	in	the	expression	of	regeneration	associated	genes,	a	phenomenon	controlled	by	the	early	activation	of	a	specific	TF	program.	TFs	are	DNA-binding
proteins	able	to	amplify	the	number	of	genes	to	switch	on/off	and	the	subsequent	cascades	of	cellular	signaling.	Both	TFs	and	miRNAs	exert	an	extensive	effect	on	gene	expression,	since	the	former	control	almost	all	genes,	whereas
the	latter	roughly	20%	of	animal	transcripts.	It	is	well	known	that	TFs	[such	as	tumor	protein	p53	(p53),	c-Jun,	CREB,	RE1-Silencing	Transcription	factor	(REST),	STAT3,	Forkhead	box	O	(FOXO),	Krueppel-like	factor	(KLFs),	nuclear
factor	 kappa-light-chain-enhancer	 of	 activated	B	 cells	 (NF-kb)	 and	 SRY-box	 containing	 gene	 (Sox)]	 are	 connected	 to	 axon	 growth	 and	 regeneration	 abilities	 as	well	 as	miRNAs	 emerged	 as	 important	 players	 for	 the	 survival	 and
differentiation	of	neurons	during	development	and	after	injury	(Fineberg	et	al.,	2009;	Lagos-Quintana	et	al.,	2001).	Therefore	establishing	a	direct	link	between	TFs	and	miRNAs	can	help	to	better	understand	the	complexity	of	the	axon
growth/regeneration	process.
One	of	the	most	studied	TF	in	the	nervous	system	is	STAT3,	a	component	of	the	7	mammalian	STATs	broadly	expressed	in	cortex,	striatum,	forebrain	and	hippocampus	both	at	embryonic	and	adult	stages	(De-Fraja	et	al.,	1998).
In	adults,	STAT3	is	expressed	at	very	low	basal	level	but	for	instance	it	is	reactivated	from	6	hours	to	1	month	after	a	sciatic	nerve	injury	without	a	correspondent	re-expression	after	a	central	dorsal	column	injury	(Qiu	et	al.,	2005).
Indeed	STAT3	reactivation	seems	to	be	a	specific	paradigm	to	promote	regrowth	in	the	PNS.	However	elevated	STAT3	levels	are	present	after	optic	nerve	crush	and	STAT3	in	vitro	KO	in	hippocampal	neurons	leads	to	a	decreased
BDNF-induced	neurite	growth	(Fischer	et	al.,	2000;	Ng	et	al.,	2006).	Such	STAT3	role	can	be	regulated	by	miRNA	activity.	STAT3	inhibition	by	two	different	miRNAs	(miR-125b	and	miR-124)	has	been	demonstrated	both	in	vitro	and	in
vivo.	miR-125b	upregulation	during	SH-SY5Y	cell	differentiation	was	experimentally	correlated	to	the	downregulation	of	10	different	genes	that	in	turn	repress	pathways	involved	in	neuronal	differentiation:	for	instance,	by	inhibiting
the	 activity	 of	 GRB2-associated-binding	 protein	 2,	 miR-125b	 activates	 STAT3	 and	 its	 PI3K-AKT	 signaling	 cascade,	 known	 to	 control	 axon	 growth	 (Le	 et	 al.,	 2009)	 (Fig.	 2).	 Acting	 on	 the	 same	 pathway,	 miR-124	 is	 significantly
downregulated	in	vivo	after	 an	hypoglossal	motor	neuron	 injury,	 suggesting	 that	 its	 repression	has	a	 crucial	 role	 for	 an	appropriate	nerve	 regeneration	by	 the	 consequent	STAT3	upregulation.	The	positive	effect	due	 to	miR-124
downregulation	can	be	also	enhanced	by	the	simultaneously	upregulation	of	KLF6,	another	growth	promoting	TF	(Nagata	et	al.,	2014)	(Fig.	2).	The	importance	of	miR-124	effect	on	STAT3	is	also	demonstrated	in	cultured	hippocampal
neurons:	when	induced	by	a	specific	small	interfering	RNA	(siRNA)	in	a	methyl	donor	deficiency	mouse	model,	miR-124	upregulation	inhibits	STAT3	signaling	cascade	and	enhances	neurite	outgrowth	(Kerek	et	al.,	2013).	miR-124	is
also	known	to	regulate	Ras-related	C3	botulinum	toxin	substrate	1(Rac1)	through	Ras	homolog	gene	family,	member	A	(RhoA-GTP)	(Fig.	3)	that	is	described	as	a	regulator	of	STAT3	(Raptis	et	al.,	2011).
Fig.	2	miRNAs	in	axonal	growth	network-1,	focused	on	PTEN-AKT-mTOR;	continuous	lines	indicate	validated	interactions	and	dotted	line	identifies	an	hypothesized	interaction;	miRNAs	in	green,	red	and	black	colors	refer	respectively	to	CNS,	PNS	and	CNS-
PNS.	TFs	are	written	in	italic.	(For	interpretation	of	the	references	to	colour	in	this	figure	legend,	the	reader	is	referred	to	the	web	version	of	this	article.)
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Another	important	TF,	involved	in	different	biological	processes,	is	p53,	a	member	of	the	tumor	suppressors	family.	In	the	nervous	system	p53	is	known	as	pro-apoptotic	factor	active	in	case	of	trauma	and	neurodegenerative
diseases	(Floriddia	et	al.,	2012;	Qi	et	al.,	2016).	Moreover	p53	is	also	required	for	neurite	outgrowth	and	regeneration,	acting	on	Coronin	1b	and	Ras	related	protein	Rab13	(cytoskeleton	molecules)	as	demonstrated	both	in	vitro	in
different	cell	lines	(human	epithelial	293,	H1299,	pheocromocytoma	PC-12)	and	rat	primary	cortical	neurons	and	in	vivo	(murine	model	of	facial	nerve	injury)	(Di	Giovanni	et	al.,	2006):	in	the	last	case,	p53	KO	mice	showed	a	lower
number	of	regenerative	fibers	compared	to	WT	mice.
The	link	between	this	TF	and	miRNAs	is	well	demonstrated	in	the	following	in	vitro	experiment:	p53	upregulation	induced	by	luteolin	(a	flavonoid	present	in	vegetables)	increases	the	expression	of	miR-34a,	that	targeting
sirtuin	1	(SIRT1)	promotes	neurite	outgrowth	of	PC12	cells	(Chen	et	al.,	2015).	Similarly,	the	conditional	miR-7	ablation	in	the	murine	cortex	revealed	that	its	expression	is	essential	for	a	complete	transition	from	radial	glial	cells	to
intermediate	progenitors	acting	on	adenylate	kinase	1	and	tumor	protein	p21	factors,	two	molecules	implicated	in	the	p53	pathways.	Only	the	presence	of	miR-7	and	its	subsequent	action	on	p53	pathway	delete	the	microcephalic
phenotype	of	an	abnormal	brain	development	(Pollock	et	al.,	2014).	Moreover	miR-7	has	been	described	to	reduce	the	neurite	outgrowth	of	neuroblastoma	cell	line	in	vitro	likely	acting	on	the	same	TF	through	a	not	specified	molecular
cascade	(Chen	et	al.,	2010).
Another	important	factor	is	c-Jun	that	is	highly	expressed	during	neural	embryonic	and	postnatal	development	in	CNS,	and	then	decreased	in	adulthood	(Mellström	et	al.,	1991;	Wilkinson	et	al.,	1989).	However	its	expression
increases	again	after	the	peripheral	(but	not	the	central)	degeneration	segment	of	DRG	neurons	in	vivo	(Broude	et	al.,	1997).	C-Jun,	by	a	specific	miRNA	interaction,	can	be	indirectly	correlated	to	a	second	TF,	CREB,	a	known	target	of
PTEN	 (Gu	 et	 al.,	 2011).	 As	 shown	 in	 Fig.	 2	 (red	 lines)	 after	 an	 in	 vivo	 sciatic	 nerve	 transection	 the	 increased	 level	 of	 c-Jun	 induces	miR-222	 upregulation	 that	 in	 turn	 decreases	 PTEN	 level,	 allowing	 the	maintenance	 of	 CREB
phosphorylation.	So	that	CREB	transcriptional	control	is	the	final	step	promoting	neurite	outgrowth	(Zhou	et	al.,	2012).	miRNA-CREB	interaction	can	be	also	considered	in	the	opposite	direction,	since	CREB	can	induce	miR-132	that	in
turn	promotes	neurite	outgrowth.	This	connection	has	been	proved	in	an	in	vitro	model	of	PC12	cells	where	luteolin	induces	miR-132	expression	through	CREB-extracellular	signal–regulated	kinase	(ERK)	mediated	phosphorylation	(Lin
et	al.,	2012),	without	identifying	the	target	responsible	of	this	effect.	Vo	et	al.	(2005)	demonstrated	the	same	miRNA	function	on	PC12	cells,	providing	the	GTPase-activating	protein	Rho	GTPase	activating	protein	32	(p250GAP)	as	miR-
132	target	and	suggesting	that	in	both	works	miR-132	could	act	in	the	same	pathway	(Vo	et	al.,	2005)	(see	miR-132	in	axonal	growth	network	Fig.	3).	miR-132	and	miR-212	are	located	in	the	same	genome	locus	and	are	controlled	by
two	TFs,	CREB	and	REST.	Moreover	REST	is	the	target	of	miR-9,	one	of	the	most	expressed	miRNA	in	brain	already	mentioned	to	control	axon	length	in	vitro	and	in	vivo	(Fig.	3).	Moreover	miR-9	and	REST	seem	to	work	in	a	feedback
regulatory	loop:	during	SK-N-BE	(human	neuroblastoma	cell	line)	proliferation,	REST	represses	miR-9	expression	but	upon	differentiating	stimulus,	REST	dismission	and	CREB	activation	induce	miR-9	expression	that	in	turn	inhibits
REST	in	order	to	maintain	the	differentiation	program	(Laneve	et	al.,	2010).	As	depicted	in	Fig.	3,	REST	is	also	targeted	by	miR-124	as	recently	demonstrated	by	Doeppner	and	coworkers	(2017)Doeppner	et	al.	(2017):	in	this	study	the
authors	revealed	that	the	intraperitoneal	injection	of	lithium	after	an	in	vivo	ischemic	stroke	(mouse	model)	increased	the	level	of	miR-124	that	in	turns	represses	REST	thus	promoting	angioneurogenesis	and	axonal	plasticity	(Fig.	3)
Fig.	3	miRNAs	in	axonal	growth	network-2	(2.1-2.2),	whose	core	molecules	are	represented	by	GSK-3β,	Rac1,	RhoA	and	PI3k/AKT;	miRNAs	in	green	and	red	colors	refer	respectively	to	CNS	and	PNS.	Continuous	lines	indicate	validated	interactions,	whereas
dotted	line	hypothesized	interactions.	TFs	are	written	in	italic.	(For	interpretation	of	the	references	to	colour	in	this	figure	legend,	the	reader	is	referred	to	the	web	version	of	this	article.)
alt-text:	Fig.	3
(Doeppner	et	al.,	2017).	Since	miR-9	is	widely	expressed	in	neurons	and	involved	in	several	biological	processes,	is	not	surprising	it	was	found	to	be	involved	in	a	feedback	regulatory	loop	with	tailess	(TLX),	a	forebrain-restricted	TF
that	 regulates	neurogenesis	maintaining	neural	 stem	cells	 (NSCs)	 in	 an	undifferentiated	proliferative	 state	 (Roy	et	al.,	 2004;	Shi	 et	 al.,	 2004).	 Indeed	miR-9	negatively	 regulates	NSC	and	 retinal	 progenitor	 cell	 proliferation	and
accelerates	differentiation	directly	 inhibiting	TLX	 that	 in	 turn	 is	 able	 to	 repress	miR-9	 in	 a	 regulatory	 loop	necessary	 to	have	a	proper	balance	between	NSC	proliferation	and	differentiation	 (Hu	et	 al.,	 2014;	Zhao	 et	 al.,	 2009).
Producing	the	same	effect	of	miR-9	on	NSCs,	also	other	miRNAs	participate	in	this	regulatory	loop	such	as	let-7b	(also	acting	on	protein	phosphatase	2	catalytic	subunit	alpha),	let-7a	and	let-7d	that	inhibits	TLX	that	in	turn	upregulates
miR-9	level	(Ni	et	al.,	2014;	Song	et	al.,	2015;	Zhao	et	al.,	2010a;	Zhao	et	al.,	2013).	On	the	contrary,	TLX	inhibits	two	miRNAs	(miR-219	and	miR-137)	that	negatively	regulate	NSC	proliferation	(Murai	et	al.,	2016;	Sun	et	al.,	2011).
Other	TFs	targeted	by	miR-9	belong	to	the	FOXO	family	known	to	maintain	the	proliferative	potential	of	neural	stem	cells.	Indeed	a	coordinated	action	of	miR-9	on	FOXO1	contributes	to	neural	stem/progenitor	differentiation
(Kim	et	al.,	2015).	FOXO1	as	well	as	Forkhead	box	P2	(Foxp2)	(another	member	of	the	same	family)	are	both	targets	of	miR-9	and	miR-132,	and	the	second	one	might	contribute	to	the	progression	of	Alzheimer’s	disease	 through
downregulation	of	tau	protein	networks	(Lau	et	al.,	2013).	Both	these	miRNAs	and	Foxp2	are	known	to	be	involved	in	neurite	outgrowth	during	development;	however	a	precise	control	of	neurite	extension	during	cortical	development
seems	to	be	achieved	by	the	convergent	action	of	miR-9	and	miR-132	to	regulate	the	expression	of	Foxp2	(Fig.	3)	(Clovis	et	al.,	2012).	miR-9	also	contributes	to	modify	motor	neuron	columnar	organization	and	axonal	projection	by
acting	on	Foxp1	during	development	of	spinal	cord	chicken	embryos	(Otaegi	et	al.,	2011).
Finally,	another	TF	known	to	play	a	crucial	role	in	spinal	cord	injury	is	Sox11,	a	member	of	the	20	Sox	family	factors	expressed	in	neural	differentiation	both	in	CNS	and	PNS	(Hargrave	et	al.,	1997;	Uwanogho	et	al.,	1995).
Higher	level	of	Sox11	are	detectable	both	after	optic	nerve	injury	in	regenerating	zebrafish	model	and	in	DRG	neurons	when	the	regenerative	program	starts	(Tanabe	et	al.,	2003;	Veldman	et	al.,	2007).	The	corticospinal	tract	after	SCI
fails	 to	express	Sox11,	while	 its	expression	 induced	by	viral	vectors	promotes	sprouting	and	axon	growth	at	both	acute	and	chronic	phase	(Wang	et	al.,	2015b).	This	effect	can	be	explained	by	the	ability	of	Sox11	to	 increase	the
expression	of	BDNF	and	induce	the	neurogenic	differentiation	of	endogenous	neural	stem	cells	after	SCI	(Guo	et	al.,	2014).	Even	if	Sox11-miRNA	connection	has	not	been	experimentally	proved,	 it	 is	possible	to	hypothesize	a	link
between	miR-145	and	Sox2,	another	TF	of	the	same	family	involved	in	neural	differentiation	after	SCI.	Indeed	several	works	demonstrated	the	requirement	of	Sox2-positive	cells	for	spinal	cord	regeneration	in	xenopus	tadpoles	and
xenopus	laevis	SCI	model	(Gaete	et	al.,	2012;	Muñoz	et	al.,	2015).	In	murine	SCI	model	Sox2	mediated	reprogramming	by	virus	injection	was	able	to	induce	the	generation	of	new	neurons,	a	mechanism	poorly	activated	in	mammals
after	SCI	(Wang	et	al.,	2016b).	This	phenomenon	can	be	related	to	the	upregulation	of	miR-145	after	in	vivo	SCI	contusion:	this	miRNA	directly	recognizes	Sox2	in	neural	stem	cells,	while	the	anti-miR-145	reverts	the	effect	on	the
target	(Morgado	et	al.,	2016).
Therefore	miRNAs	and	transcription	factors	are	strictly	intertwined	and	act	as	a	powerful	regulatory	network	in	controlling	axon	growth	and	regeneration.
5	MiRNAs	IN	AXONAL	GROWTH	NETWORK:	PTEN	PATHWAYin	axonal	growth	network:	PTEN	pathway
miRNAs	participate	in	one	of	the	main	molecular	cascades	regulating	axon	growth,	i.e.	the	PTEN	pathway.	Indeed,	acting	as	an	inner	regulatory	system,	they	represent	a	promising	tool	still	quite	mostly	unexplored.	As	shown	in
Fig.	2,	axonal	growth	is	under	the	control	of	different	growth	factors,	such	as	nerve	growth	factor,	that	stimulate	the	conversion	of	lipid	second	messenger	phosphatidylinositol	(4,5)	bisphosphate	(PIP2)	into	phosphatidylinositol	(3,4,5)
trisphosphate	(PIP3)	by	PI3K.	Then	PIP3	activates	AKT	through	phosphatidylinositol-dependent	kinase	1/2	(PDK1/2)	recruitment.	AKT	in	turn	switches	on	a	large	spectrum	of	downstream	effectors.	Among	them,	the	mechanistic	target
of	rapamycin	(mTOR)	synthetizes	raw	material	for	axon	extension	and	GSK-3β	promotes	cytoskeleton	reorganization	(as	shown	further	in	Fig.	3).	Unfortunately,	after	an	injury,	this	pathway	is	inhibited	by	PTEN	that	antagonizes	PI3K
activity,	 thus	 resulting	 in	 the	 failure	of	axon	 regeneration	 (Chadborn	et	 al.,	 2006;	Park	et	 al.,	 2010;	Rodgers	and	Theibert,	2002).	 To	promote	neuronal	 regeneration,	 several	 strategies	 (molecular	deletion,	 shRNA,	 antagonists	 or
inhibitors)	have	been	applied	at	different	levels	of	this	cascade.	However,	until	now,	none	of	them	can	be	completely	restored	the	pre-injury	condition,	due	to	the	complex	network	of	cooperating	molecules	that	orchestrate	the	different
steps	of	the	process.	Based	on	the	literature	(Li	and	Sun,	2013;	Zhang	et	al.,	2013;	Zou	et	al.,	2015a;	Zou	et	al.,	2015b),	we	identified	a	miRNA	network	acting	on	the	PTEN	pathway	(Fig.	2).	miR-17-92	cluster	and	miR-26a	directly
repress	PTEN	expression	in	primary	cortical	neurons	during	development,	whereas	miR-29a	and	miR-29c	have	the	same	effect	on	PC12	neural	differentiating	cell	lines.	When	these	miRNAs	are	overexpressed,	PTEN	protein	levels
decrease	to	41%	(miR-17-92	cluster),	38.3%	(miR-26a)	44%	(miR-29a),	and	54%	(miR-29c),	validating	this	molecule	as	one	of	their	main	targets.	Further	evidence	of	the	effect	of	these	miRNAs	on	PTEN	is	the	upregulation	of	some
downstream	effectors,	such	as	mTOR	and	AKT:	the	downregulation	of	PTEN	is	thus	associated	with	the	enhancement	of	axonal	outgrowth	for	miR-17-92	and	of	neurite	outgrowth	for	miR-29a	miR-29c	and	miR-26a.	Indeed	the	inhibition
of	miR-17-92	cluster	revealed	a	suppressed	axonal	growth	by	50%	during	60	min	of	in	vitro	observation.	miR-21	is	involved	in	decreased	expression	of	PTEN	as	well.	It	contributes	to	explain	the	mechanism	underlying	the	benefits	of
docosahexaenoic	acid	(DHA),	a	fatty	acid	promoting	functional	recovery	after	SCI.	In	fact,	DHA	in	vivo	administration	significantly	upregulates	miR-21	that	in	turn	downregulates	PTEN	in	corticospinal	neurons.	The	decreased	PTEN
levels	are	accompanied	by	an	increase	in	neurite	outgrowth	of	primary	cortical	neurons	in	vitro,	supporting	a	key	role	for	miR-21	in	the	enhancement	of	neuroplasticity	after	SCI.	Similarly	in	vivo	a	single	acute	(1-2	days),	but	not
delayed,	administration	of	DHA	induces	a	significant	sensorymotor	and	functional	recovery	after	rat	cervical	hemisection	(Liu	et	al.,	2015c).	miR-26a	and	miR-222	have	been	described	to	repress	PTEN	respectively	in	bupivacaine	DRG
induced	nerve	injury,	and	in	adult	DRG	after	sciatic	nerve	transection	models,	thus	promoting	nerve	regeneration	(Cui	et	al.,	2015;	Zhou	et	al.,	2012).	Some	small	RNAs	indirectly	influence	mTOR	or	AKT	in	order	to	reach	the	same
goal.	For	example,	miR-222	has	been	 studied	both	 in	vitro	 (PC12	cell	 line)	 and	 in	vivo	 (laryngeal	 nerve	 injury	 in	 rabbit):	when	activated	by	BDNF	administration,	miR-222	acts	 as	 a	promoter	 of	mTOR	upregulation	 (probably	by
inhibiting	PTEN,	dotted	line	in	Fig.	2),	significantly	 inducing	neurite	outgrowth,	 increasing	the	number	of	regenerating	fibers,	decreasing	fibrous	connective	tissue	and	restoring	nerve	conduction	velocity.	Similarly,	when	SCI	rats
undergo	cycling	exercise	to	stimulate	neuron	regenerative	potential,	the	expression	of	miR-199-3p	is	reduced	and	mTOR	expression	results	increased:	the	raised	regenerative	neuronal	potential	observed	should	be	attributed	to	the
synergistic	effects	of	miR-199-3p	and	miR-21,	 that	are	 responsible	 for	PTEN	mRNA	decrease	 (Liu	et	al.,	2012;	Xie	et	al.,	2015).	Moreover	also	miR-124	 indirectly	 targets	AKT	 through	 the	 repression	of	 rho-associated	coiled-coil-
containing	protein	kinase	1	(ROCK1),	a	protein	serine/threonine	kinase	and	the	major	downstream	effector	of	RhoA	GTPase.	Gu	et	al.	determined	that	the	PI3	K/AKT	signalling	acts	downstream	ROCK1	whose	repression	by	miR-124	can
activate	AKT.	The	activated	AKT	is	then	able	to	induce	neurite	outgrowth	and	elongation	during	neural	development	of	neuroblastoma	cell	line	[BE	(2)	M17]	and	mouse	P19	cells	(Gu	et	al.,	2014).
Recently	 another	miRNA	 emerged	 as	 a	 new	 regulator	 of	 PTEN	pathway:	 indeed	 the	 overexpression	 of	miR-182	 in	 cultured	murine	 cortical	 neurons	 increases	 the	 complexity	 of	 the	 dendritic	 branches	 and	 promote	 axon
outgrowth	by	inhibiting	PTEN	and	activating	AKT	signal	through	a	decreased	expression	of	branched-chain	aminotransferase	(BCAT2)	(Wang	et	al.,	2017)	(orange	line	Fig.	2).
6	MiRNAs	IN	AXONAL	GROWTH	NETWORK:	GSK-3β	PATHWAYin	axonal	growth	network:	GSK-3β	pathway
During	development,	axon	growth	is	mediated	by	several	pathways	that	can	be	reactivated	and/or	inhibited	in	the	mature	nervous	system	as	a	consequence	of	a	lesion.	Moreover,	one	single	molecule	can	participate	in	different
pathways	and/or	be	the	target	of	different	miRNAs.	A	paradigmatic	example	of	these	intersections	is	represented	by	miR-124,	previously	involved	in	neurite	elongation	of	M17	cells	(neuroblastoma	cell	line)	in	vitro	through	ROCK1-
PI3K/AKT	regulation	(Gu	et	al.,	2014).	As	shown	in	Fig.	3,	PI3K/AKT	signaling	is	also	linked	to	axonal	microtubule	assembly.	The	inhibition	of	GSK-3β	leads	to	the	dephosphorylation	of	GSK-3β	substrates	that	regulate	the	dynamics	and
stability	of	axon	microtubules	(Zhou	and	Snider,	2006).	PI3K-GSK-3β	signal	represents	a	key	step	in	the	axon	specification	and	growth	of	hippocampal	neurons	(Jiang	et	al.,	2005;	Yoshimura	et	al.,	2005),	making	possible	to	establish	a
connection	between	miR-124	and	GSK-3β	through	PI3K-AKT	signal	(blue	dotted	line).	Recently,	it	has	been	shown	that	miR-124	operates	synergistically	with	miR-9	to	promote	neuronal	differentiation	and	dendritic	branching	of	neural
stem	cells:	 these	miRNAs,	 repressing	 their	 common	 target	 (Rap2a	protein),	 elicit	 the	 inhibition	of	Rap2a	protein	 on	AKT.	AKT	 in	 its	 active	 form	phosphorylates	 and	 suppresses	GSK-3β	 thus	 leading	 to	neuronal	 development	 and
maturation	(Hur	and	Zhou,	2010).	GSK-3β	could	be	also	a	downstream	effector	of	the	wnt-β-catenin	cascade,	which	is	activated	after	SCI	and	promotes	several	biological	functions	including	axon	remodeling.	In	the	classical	pathway,
wnt	binds	to	its	receptors	(Low-density	lipoprotein	receptor-related	protein	5	and	frizzled)	to	signal	to	the	GSK-3β/adenomatous	polyposis	coli	(APC)	complex	and	finally	to	β-catenin	that	translocates	to	the	nucleus	to	elicit	a	change	in
the	cytoskeleton	components.	However,	wnt	inhibitors	(like	Dickkopf-related	protein	1	(Dkk-1)	and	Kremen	1)	are	overexpressed	early	after	a	SCI	or	nerve	crush,	thus	inhibiting	the	cellular	processes	activated	by	β-catenin	(Fernández-
Martos	 et	 al.,	 2011).	 As	 illustrated	 in	 Fig.	 2,	GSK-3β	 could	 be	 the	 converging	 point	 of	 two	molecular	 cascades	 (PI3K-AKT-	 GSK-3β/APC	 and	wnt-β-catenin-GSK-3β)	 that	 probably	 reach	 the	 same	 effect,	 i.e.	 the	 reorganization	 of
microtubules.	Moreover	 as	 reported	 in	 subsection	 4,	miR-9	 and	 TLX	 are	 involved	 in	 a	 feedback	 regulatory	 loop	 that	 control	 neurogenesis:	 also	 GSK-3β	 downregulates	 TLX	 together	 with	 high	 IL-1β	 upregulation	 thus	 inhibiting
hippocampal	neurogenesis.	Indeed	both	GSK-3β,	TLX	and	IL-1β	are	dysregulated	in	neurodegenerative	and	psychiatric	disorders	suggesting	that	a	complex	interaction	among	all	these	factors	could	result	in	a	complete	regulation	of
neurogenesis	and	axon	growth	(Green	and	Nolan,	2012).
Another	miRNA	 can	 be	 inserted	 in	 the	 wnt-β-catenin-GSK-3β	molecular	 cascade	 as	 a	 regulatory	molecule	 of	 the	 cytoskeleton	 dynamics.	 Indeed	miR-431	 is	 induced	 after	 sciatic	 nerve	 crush	 and	 is	 able	 to	 stimulate	 the
regeneration	of	cultured	DRG	axons	silencing	Kremen-1,	an	antagonist	of	wnt-β-catenin	signaling	(Wu	and	Murashov,	2013):	Kremen	1	was	identified	as	one	of	the	main	targets	of	miR-431;	moreover,	the	in	vivo	mRNA	and	protein
expression	in	DRG	neurons	is	reduced	in	presence	of	miR-431.	The	effect	of	this	miRNA	consists	in	a	significant	increase	in	axon	length	(about	30%)	after	its	overexpression,	whereas	cells	treated	with	a	miR-431	inhibitor	display	a
reduction	in	axon	branching	by	35%.	Similarly,	evidence	of	miRNA	action	on	GSK-3β	has	been	demonstrated	by	the	administration	of	miR-26a	inhibitor	after	a	nerve	crush	that	can	impair	in	vivo	axon	regeneration.	The	endogenous
regulatory	effect	of	miR-26a	is	mediated	again	by	GSK-3β	as	demonstrated	by	in	vitro	and	in	vivo	experiments	in	DRG	neurons.	However,	in	this	case,	GSK-3β	has	a	direct	effect	on	gene	expression	controlling	the	TF	SMAD1,	a	TF
known	to	promote	axon	outgrowth	after	axotomy	(Saijilafu	et	al.,	2013;	Zou	et	al.,	2009).	GSK-3β	regulation	of	axon	growth	is	mediated	both	via	controlling	microtubules	dynamics,	at	the	growth	cone	level,	or	via	controlling	gene
expression	at	the	soma	level	(Jiang	et	al.,	2015).	We	can	finally	conclude	that	a	low	level	of	GSK-3β	needs	to	be	endogenously	maintained	by	miRNAs	in	order	to	support	an	efficient	regeneration	process.
7	MiRNAs	IN	AXONAL	GROWTH	NETWORK:	MAP1B-Rac1	PATHWAYin	axonal	growth	network:	MAP1B-Rac1	pathway
The	mitogen-activated	protein	kinase	(MAPK)	system	is	found	upstream	GSK-3β	activation	and	makes	it	phosphorylate	MAP1B	stimulating	axon	growth	(Goold	and	Gordon-Weeks,	2005):	this	link	has	been	proved	in	a	context	in
which	NGF	partially	contributes	to	axon	elongation	through	MAPK-	GSK-3β-MAP1B	cascade	(Fig.	3).	MAP1B	is	also	the	target	of	miR-9,	an	highly	conserved	miRNA	detected	in	the	axon	of	primary	cortical	neurons.	By	acting	locally	in
the	axon,	this	miRNA	is	able	to	control	axon	length	both	in	vitro	(E17	primary	cortical	neurons)	and	in	vivo	(E	14.5	embryos	brain)	during	development.	In	particular,	the	axon	extension	is	allowed	by	preventing	the	interaction	between
miR-9	and	MAP1B	(Dajas-Bailador	et	al.,	2012):	the	authors	attributed	this	effect	to	a	short	stimulation	with	BDNF	and	the	consequent	increase	of	MAP1B	protein	level.	MAP1B	is	a	fundamental	stabilizer	of	axonal	microtubules,	and	it
is	highly	expressed	at	the	distal	tip	of	the	growing	axons.	Indeed	MAP1B	deficient	mice	present	a	delay	in	axon	outgrowth	and	a	reduced	rate	of	its	elongation.	Montenegro-Venegas	et	al.	(2010)	demonstrated	the	role	of	this	protein	in
the	cross-talk	between	microtubules	and	actin	filament:	when	MAP1B	is	present,	T-cell	lymphoma	invasion	and	metastasis	2	(TIAM1,	a	guanine	exchange	factor)	binds	to	microtubules,	activates	Rac1	that	in	turn	inhibits	cofilin,	thus
allowing	 actin	 polymerization	 and	 axon	 growth	 (the	 pathway	 is	 briefly	 illustrated	 in	 Fig.	 3).	 Considering	 the	miR-9	 effect	 on	 primary	 cortical	 neurons	 through	MAP1B	 silencing,	we	 can	 suppose	 that	miR-9	 suppresses	 the	 axon
elongation	process	acting	on	this	pathway.	Moreover	one	of	its	first	elements	(Rac1	GTP,	the	activated	form	of	Rac1)	is	a	“crossroad”	directed	to	different	molecules	and	signal	cascades,	and	possibly	regulated	by	several	miRNAs,	like
miR-9,	miR-124	and	miR-132	(Fig.	3).	Indeed	the	last	one	(whose	expression	is	highly	induced	by	neurotrophins	and	CREB)	promotes	neurite	outgrowth	by	p250GAP,	a	Rho	family	GTPase-activating	protein,	inhibition	during	cortical
neuron	morphogenesis	 in	vitro	(Vo	et	al.,	2005):	 its	downstream	molecules	can	be	pinpointed	 in	Rac1	pathway,	 involved	 in	actin	polymerization	 (Fig.	3,	dotted	yellow	 lines).	 Indeed,	 the	 link	miR-132-p250GAP-Rac1-	p21-activated
kinases	(PAK)	is	involved	in	the	remodeling	and	maintenance	of	spine	growth	and	probably	in	the	axon	growth	(Lai	and	Ip,	2013).
8	MiRNAs	IN	AXONAL	GROWTH	NETWORK:	RhoA-PI3K-AKT	PATHWAYn	axonal	growth	network:	rhoA-PI3K-AKT
pathway
Another	molecule	controlled	by	miRNAs	in	the	axonal	growth	network	is	MAP1B.	According	to	the	role	attributed	to	MAP1B	during	axon	development	(Del	Rı́o	et	al.,	2004;	DiTella	et	al.,	1996;	Montenegro-Venegas	et	al.,	2010),
it	activates	Rac1	pathway	that	inhibits	RhoA,	thus	avoiding	the	growth	cone	collapse	(Fig.	3).	Similarly,	miR-133b	is	a	suppressor	of	RhoA,	contributing	in	vitro	to	neurite	outgrowth	both	in	PC12	cell	lines	and	primary	cortical	neurons
(E18;	(Lu	et	al.,	2015)).	Extracellular	signal-regulated	kinases	and	PI3K/AKT	are	the	main	effectors	of	the	signaling	pathway	downstream	miR-133-RhoA.	As	already	described	above,	PI3K/AKT	is	one	of	the	best	known	pathway	involved
in	axon	growth	and	is	probably	linked	to	GSK-3β,	another	key	player	of	such	process.	The	role	of	miR-133	emerges	even	more	significant	if	we	consider	the	work	of	Xin	et	al.	(2012):	neurite	outgrowth	of	primary	cultured	neurons
isolated	from	post-middle	cerebral	artery	occlusion	brain	was	stimulated	by	miR-133b-enriched	exosomes	derived	from	mesenchymal	stromal	cells,	through	RhoA	repression.	Therefore	miR-133	seems	to	be	responsible	for	axon	growth
not	only	during	development,	but	also	during	brain	repair	(Xin	et	al.,	2012).	In	addition,	Yu	et	al.	(2011a,b)	described	the	essential	role	of	miR-133	after	SCI	in	adult	zebrafish.	miR-133	is	endogenously	overexpressed	six	hours	after	the
lesion,	but	 its	 inhibition	blocks	 the	 regeneration	process	 increasing	RhoA	protein	 level,	 thus	 likely	 activating	 the	growth	cone	 collapse	 (Fig.	3,	 brown	dotted	 lines).	 Indeed	 the	 injured	adult	 zebrafish,	 following	miR-133	 inhibitor
administration,	showed	a	reduced	locomotor	recovery	and	a	low	number	of	neurons	with	regenerating	axons	(Yu	et	al.,	2011b).	Its	beneficial	effect	has	been	recently	demonstrated	also	in	mammals	by	the	lentiviral	injection	of	miR-
133b	 in	an	adult	 injured	 spinal	 cord:	RhoA	has	been	validated	as	 its	direct	 target,	whose	donwnregulation	was	associated	 to	mice	 locomotor	 recovery	already	at	4	weeks	after	 the	 lesion	 (Theis	et	al.,	2016).	 Finally,	 the	 indirect
connection	among	other	two	miRNAs	with	RhoA	pathway	was	demonstrated	by	Sun	et	al.	(2013),	that	analyzed	the	mechanism	of	action	of	the	heat	shock	protein	B1	(HspB1).	HspB1	is	able	to	repress	RhoA	(thus	promoting	neurite
extension),	silencing	the	Rho	GTPase,	Rho	guanine	nucleotide	exchange	factor	11	(PDZ-RhoGEF),	an	exchanging	factor	that	promotes	the	switch	between	RhoA	GDP	(inactive)	and	GTP	active.	PDZ-RhoGEF	repression	is	driven	by	miR-
20a	and	miR-128,	whose	expression	is	specifically	enhanced	by	HspB1	((Sun	et	al.,	2013)	violet	dotted	line,	Fig.	3).	In	fact,	inhibitors	of	miR-20a	and	miR-128	block	the	neurite	growth	of	E17	cortical	neurons	promoted	by	HspB1,	thus
confirming	the	molecular	cascade	analyzed.	Even	though	the	downstream	effectors	of	RhoA	are	not	described	here,	it	can	be	reasonably	supposed	a	connection	with	the	PI3	K/AKT	pathway	that	directly	promotes	neurite	growth	(brown
dotted	line	Fig.	3).	In	conclusion,	this	molecular	cascade	could	be	a	pivotal	pathway	not	only	during	development,	but	also	after	an	injury.	Indeed	all	the	molecules	described	have	been	found	in	neurites	and	growth	cones,	and	are
produced	in	the	axonal	protein	synthesis	occurring	after	injury.
9	MiRNAs	IN	NEUROINFLAMMATION	FOLLOWINGin	neuroinflammation	following	SCI
The	pathophysiology	of	SCI	is	also	characterized	by	the	activation	of	the	inflammatory	response	to	the	lesion.	miRNAs	are	one	of	the	main	regulators	of	inflammation	in	several	neurodegenerative	diseases	[multiple	sclerosis,
ALS	and	Alzheimer’s	disease,	for	example]	as	well	as	in	SCI.	Here	we	describe	one	of	the	most	common	inflammatory	pathways,	analyzing	the	contribution	of	some	miRNAs	altered	after	SCI.	As	shown	in	Fig.	4,	the	nuclear	factor
kappa	B	 (NF-kB)	 canonical	 pathway,	 a	 transcription	 factor	 for	 cytokines,	 adhesion	molecules	 and	 anti-apoptotic	 proteins,	 can	 be	 activated	 by	 different	 extracellular	 signals	 such	 as	 TNF-α	 and	 interleukin	 1	 (IL-1).	 Through	 their
receptors,	they	activate	IKK,	constituted	by	IKK-α	IKK-β	and	IKK-γ,	that	induces	the	phosphorylation	of	nuclear	factor	of	kappa	light	polypeptide	gene	enhancer	in	B-cells	inhibitor	alpha	(IkBα),	an	inhibitory	protein	bound	to	NF-kB.	The
IkBα	phosphorylation	results	in	its	release	by	NF-kB	that	is	translocated	to	the	nucleus	by	importin	(Baeuerle	and	Baltimore,	1988;	Baldwin,	1996).	Here	it	can	bind	the	DNA,	thus	inducing	the	production	of	pro-inflammatory	cytokines.
The	immune	mediator	TNF-α	is	the	first	target	of	four	different	miRNAs.	This	pro-inflammatory	and	pro-apoptotic	factor	increases	after	injury,	but	its	expression	can	be	modulated	by	miR-181a,	miR-125b,	miR-411	and	miR-99a.	In
normal	conditions,	miR-181a	is	enriched	in	astrocytes	both	in	culture	and	in	mouse	cerebral	cortex	in	vivo;	however,	its	in	vitro	(primary	astrocytes	culture)	knocking	down	enhances	the	production	of	cytokines	such	as	TNF-α	or	IL-6
(Hutchison	et	al.,	2013).	Whether	these	molecules	are	the	direct	targets	of	miR-181a	is	not	fully	understood:	indeed	Hutchinson	et	al.	(2013)	have	conferred	a	neuroinflammatory	role	to	this	miRNA,	validating	methyl	CpG	binding
protein	 2	 (MecP2)	 and	 x-linked	 inhibitor	 of	 apoptosis	 protein	 (XIAP)	 as	 its	 direct	 targets.	 These	 two	molecules	 are	 generally	 involved	 in	 apoptosis,	 but	 are	 likely	 also	 connected	 in	 astrocytes	 responses.	Moreover,	miR-181a	 is
downregulated	in	a	contusive	SCI	model	7	days	post	injury	(Liu	et	al.,	2009)	with	a	good	correlation	between	the	microarray	data	and	the	RT-PCR	results.	The	role	of	miR-181,	analyzed	by	miRanda	database,	revealed	TNF-α	as	one	of
its	potential	targets.	In	a	similar	experiment	with	a	model	of	moderate	contusive	SCI,	microarray	data	showed	a	decreased	level	of	miR-181	after	injury,	and	the	pathway	analysis	of	the	networks	affected	by	miRNAs	put	this	small	RNA
as	a	controller	of	the	inflammatory	process	(Yunta	et	al.,	2012).	Conversely,	miR-125b	directly	targets	the	3′	untranslated	region	of	TNF-α	transcript,	thus	controlling	its	production	in	the	endotoxin	shock	(Tili	et	al.,	2007).	Even	though
here	is	not	related	to	CNS,	we	hypothesize	that	the	NF-kB	pathway	is	conserved	in	different	systems.	Liu	et	al.	(2009)	described	also	a	downregulation	of	miR-125,	hypothesizing	that	changes	 in	 its	expression	could	be	related	to
infiltration	and	activation	of	astrocytes	and	other	cells	types.	Despite	they	did	not	describe	a	clear	role	for	this	miRNA,	there	is	a	consistent	literature	conferring	an	inflammatory	role	to	miR-125	(Pogue	et	al.,	2010;	Tili	et	al.,	2007;	Xia
et	 al.,	 2009).	 Also	miR-411	 and	miR-99a	 have	 been	 related	 to	 TNF-α	 by	 in	 silico	 prediction.	 The	 connection	with	 this	 cytokine	 is	 even	 stronger	 considering	 their	 in	 vivo	 downregulation	 after	 SCI,	 that	 should	 lead	 to	 increased
inflammation	(Liu	et	al.,	2009;	Yunta	et	al.,	2012).	Proceeding	through	the	pathway,	miR-9,	miR-199	and	miR-146a	are	negative	regulators	of	NF-kB,	IKK-β,	and	NF-kB	respectively.	Based	on	prediction	data,	the	in	vivo	downregulation
of	miR-9	and	miR-199	after	SCI	leads	to	higher	level	of	NF-kB	and	IKK-β	(Chen	et	al.,	2008;	Wang	et	al.,	2011).	The	link	between	these	miRNAs	and	their	targets	is	based	on	some	demonstrations	derived	by	inflammation	and	cancer
studies,	that	make	this	connection	likely	valid	also	for	the	traumatic	conditions.	IKK-β	has	been	identified	for	the	first	time	as	a	target	of	miR-199	in	a	study	relative	to	the	inflammatory	properties	of	ovarian	cancer	cells	(Chen	et	al.,
2008).	Moreover	after	an	acute	SCI	miR-199b	levels	in	activated	microglia	decrease	with	a	consequent	activation	of	IKK-β-NF-kB	signaling	pathway.	In	vivo	overexpression	of	this	miRNA	reverses	the	upregulation	of	its	target	(IKK-β)
resulting	in	the	suppression	of	inflammatory	response	and	improving	animal	performance	(grip	strength	and	rotarod	tests)	(Zhou	et	al.,	2016).	On	the	other	hand,	Bazzoni	et	al.	(2009)	showed	that	miR-9	(human	polymorphonuclear
neutrophils	and	monocytes)	acts	on	NF-kB	with	a	feedback	control	loop	in	which	NF-kB	increases	miR-9	that	in	turn	tunes	its	levels	(Bazzoni	et	al.,	2009).	The	same	auto-regulatory	loop	has	been	demonstrated	both	for	miR-9	by	Wang
et	al.	(2011)	in	hepatoma	cells	(Wang	et	al.,	2011),	and	for	miR-146a	whose	increased	expression	7	days	after	injury	negatively	represses	NF-kB	(Bethea	et	al.,	1998;	Taganov	et	al.,	2006).	miR-146a	is	expressed	in	reactive	cultured
human	astrocytes	and	its	overexpression	has	an	anti-inflammatory	effect,	reducing	the	levels	of	several	cytokines	as	IL-6	(Iyer	et	al.,	2012;	Liu	et	al.,	2009;	Yunta	et	al.,	2012).	Indeed	its	expression	has	been	correlated	with	a	positive
functional	score	after	SCI,	revealing	its	concrete	anti-inflammatory	role	(Strickland	et	al.,	2011a).	Moreover	miR-146a	has	been	recently	involved	in	a	feedback	mechanism	(Fig.	4):	its	upregulation	in	SCI	is	driven	by	proinflammatory
cytokines,	whose	expression	increases	in	vivo	during	the	firsts	day	after	SCI.	Indeed	the	induced	miR-146a	overexpression	in	acute	phase	is	a	consequence	of	the	initial	inflammation	which	is	then	blocked	by	interleukin	1	receptor
associated	kinase	1-	TNF	receptor	associated	factor	6	(IRAK1-TRAF6-MAPK)	inactivation	by	miR-146a	(Wei	et	al.,	2016).	Therefore,	the	authors	indicated	miR-146a	as	a	potential	therapeutic	anti-inflammatory	target	in	SCI.	Finally,	let-
7	results	downregulated	at	1,	3	and	7	days	post	injury	(Nieto-Diaz	et	al.,	2014).	This	miRNA	directly	inhibits	IL-6	during	the	inflammatory	response	related	to	cancer	cell	transformation	(Iliopoulos	et	al.,	2009).
Fig.	4	miRNAs	in	inflammation,	with	particular	emphasis	on	cytokines	(TNF-α,	IL-1,	IL-6)	and	NF-kB	role.	P	in	the	yellow	circle	stands	for	phosphorylation.	Question	marks	indicate	an	unproved	interaction	between	the	molecules	indicated;	miRNAs	in	green
10	MiRNAs	IN	APOPTOSIS	FOLLOWINGin	apoptosis	following	SCI
The	role	of	miRNAs	appears	pivotal	also	in	orchestrating	the	mechanisms	of	apoptosis,	equally	important	during	nervous	system	development	and	in	case	of	trauma.
miRNA	biogenesis	is	essential	for	the	correct	CNS	development	as	demonstrated	by	Dicer	and	microprocessor	complex	deletion/downregulation.	In	vivo	Dicer	deletion	in	midbrain	dopamine	neuron,	Purkinje	cells,	cortical	and
hippocampal	neurons,	striatal	neurons	and	motor	neuron	progenitors	causes	apoptosis,	brain	abnormalities	and	decreases	neural	differentiation	(Chen	and	Wichterle,	2012;	Cuellar	et	al.,	2008;	Davis	et	al.,	2008;	Kim	et	al.,	2007;
Schaefer	et	al.,	2007).	More	in	detail	in	vivo	conditional	Dicer	ablation	in	dorsal	telencephalon	at	embryonical	stage	revealed	that	differentiation	and	survival	of	newborn	neurons	is	much	more	affected	by	miRNA	absence	than	the
maintenance	of	progenitor	expansion	 (De	Pietri	Tonelli	et	al.,	2008).	Also	 the	 conditional	 deletion	of	DGCR8	 in	post-mitotic	neurons	 (hippocampus	and	cortex)	partially	 causes	brain	weight	 reduction,	microcephaly	 and	apoptosis
(Babiarz	et	al.,	2011;	Shiohama	et	al.,	2003).	Moreover	the	AGO1-4	ES	cell	line	deficiency	undergoes	a	deficit	in	miRNA-mediated	translation	repression	and	apoptosis	as	a	result	of	Bim	upregulation	(Su	et	al.,	2009).
Regarding	CNS/PNS	 trauma,	as	previously	mentioned,	 the	 sequence	of	 anatomical	 changes	occurring	after	 an	 injury	 is	 also	 characterized	by	neuron	cell	 death	 through	 the	mechanism	of	 apoptosis:	during	 the	 secondary
damage	of	SCI,	it	is	modulated	by	a	variety	of	factors,	including	several	miRNAs.	At	least	7	known	miRNAs	participate	in	the	control	of	the	main	steps	of	the	apoptotic	molecular	cascade.	As	shown	in	Fig.	5,	the	main	component	of	this
pathway	consists	of	B-cell	lymphoma	2	(Bcl-2,	anti-apoptotic	factor)	that	inhibits	the	release	of	cytochrome	c	by	mitochondria	and	the	consequent	activation	of	caspases,	thus	leading	to	the	final	repression	of	the	apoptotic	process.
Moreover	other	molecular	cascades	[those	of	FAS-LL-caspase	8,	PTEN-AKT	and	second	mitochondria-derived	activator	of	caspases	(SMAC)-XIAP],	again	regulated	by	miRNAs,	can	contribute	to	the	apoptotic	mechanisms	(Jovanovic	and
Hengartner,	2006).	miR-29b	is	involved	in	cell	death	as	a	regulator	of	some	pro-apoptotic	genes	like	PUMA,	both	in	a	model	of	forebrain	ischemia	(Ouyang	et	al.,	2013)	and	SCI	(Liu	et	al.,	2015b).	Liu	et	al.	(2015b)	demonstrated	a
decreased	expression	of	miR-29b	and	an	increase	in	some	pro-apoptotic	genes	after	a	contusive	SCI:	more	in	detail,	they	demonstrated	that	transfection	of	miR-29	mimic	in	vitro	(Neuro-2A)	decreased	the	expression	of	p53	upregulated
modulator	of	apoptosis	(PUMA),	Bcl-2-associated	death	promoter,	Bcl-2-like	protein	11	and	phorbol-12-myristate-13-acetate-induced	protein	1.	Similarly,	miR-29	inhibitor	reduces	Neuro-2A	cell	viability	as	well	as	the	miR-29	mimic
abolishes	the	expression	of	active	caspase-3	in	vivo.	Therefore,	as	schematized	in	Fig.	5,	an	overexpression	of	miR-29b	could	repress	PUMA	that	generally	promotes	the	apoptotic	process	by	Bcl-2	inhibition.	Furthermore,	in	the	same
paper	the	authors	conclude	that	the	neural	cell	death	in	SCI	is	the	result	of	a	cooperative	contribution	of	miR-29b	and	miR-20a:	the	expression	of	miR-20a	increases	after	SCI	thus	directly	downregulating	its	target	Mcl-1,	an	anti-
apoptotic	factor.	However	only	the	coinjection	of	miR-20a	inhibitor	and	miR-29b	mimic	into	the	lesion	spinal	cord	completely	abolishes	caspase	3	activation.
color	refer	to	CNS.	(For	interpretation	of	the	references	to	colour	in	this	figure	legend,	the	reader	is	referred	to	the	web	version	of	this	article.)
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Bcl-2,	together	with	XIAP,	can	also	be	target	of	miR-34a	and	miR-16.	The	direct	link	between	miR-34a	and	the	two	anti-apoptotic	proteins	is	described	in	an	experimentally	induced	traumatic	brain	injury	model	in	which	miR-34
overexpression	(in	vitro	and	in	vivo)	causes	the	increase	of	caspase	11	(Truettner	et	al.,	2013).	On	the	contrary,	miR-34	downregulation	4	h	after	SCI	is	probably	an	attempt	to	contain	cell	death	(Ning	et	al.,	2014).	Thence	it	is	likely
that	miR-34	exerts	its	pro-apototic	role	directly	targeting	Bcl-2	and	XIAP	and	thus	increasing	caspase	levels	(Fig.	5).	miR-16	can	be	considered	a	proapoptotic	miRNA	as	demonstrated	by	its	in	vivo	increased	expression	10	days	after
SCI	with	a	correspondent	downregulation	of	its	target,	Bcl-2	(Liu	et	al.,	2010).
On	the	contrary,	miR-21,	whose	expression	is	increased	after	contusion	SCI	in	rats	(Hu	et	al.,	2013),	plays	a	different	role.	Knocking	down	miR-21	with	antagomir-21	attenuates	the	recovery	of	hindlimb	motor	function	with	a
decreased	spinal	tissue	sparing	and	increased	lesion	volume.	Moreover	the	anatagomir-21	group	causes	increased	apoptosis	following	SCI,	with	FAS-L	and	PTEN	validated	as	direct	targets	or	miR-21.	Indeed,	in	vivo	treatment	with
anatagomir-21	results	 in	 increased	FAS-L	and	PTEN	 level,	both	apoptotic	promoters	 through	Fas	cell	 surface	death	receptor	−associated	protein	with	Death	Domain-CASPASE	8	 (Fas-FADD-CASPASE	8)	and	AKT	cascade	 (Fig.	 5).
Moreover	 through	 Fas-FADD-CASPASE	 8	 pathway	 miR-200c	 seems	 to	 be	 involved	 in	 the	 FAS-FAS-L	 interaction	 by	 directly	 targeting	 FAS	 associated	 phosphatase-1	 (FAP-1).	 miR-200c	 is	 significantly	 increased	 after	 SCI	 and	 its
upregulation	in	BV-2	cells	dramatically	promotes	apoptosis,	downregulating	FAP-1	and	thereby	activating	FAS	signaling	cascade	(Yu	et	al.,	2014).
Furthermore	PTEN	is	also	the	target	of	miR-494,	a	miRNA	downregulated	after	SCI	contusion	in	rats.	Restoring	the	normal	expression	of	this	miRNA	inhibits	apoptosis	and	promotes	functional	recovery	after	SCI	in	mice	(Zhu
et	al.,	2017).	In	this	case	it	has	been	recently	described	that	miR-494	activity	is	regulated	by	another	small	RNA:	lncRNA-XIST,	a	long	non	coding	RNA	whose	upregulation	after	SCI	reduces	the	beneficial	activity	of	miR-494	(Gu	et	al.,
2017).	Finally,	also	caspase	activation	is	regulated	by	some	miRNAs.	As	previously	described	by	a	microarray	analysis,	miR-30b	and	miR-30c	are	both	downregulated	after	a	spinal	cord	contusion	(Liu	et	al.,	2009).	Caspase	3	is	a	main
Fig.	5	miRNAs	in	the	apoptotic	pathway	in	which	Bcl-2	and	caspases	are	the	main	players;	miRNAs	in	green	color	refer	to	CNS.	(For	interpretation	of	the	references	to	colour	in	this	figure	legend,	the	reader	is	referred	to	the	web	version	of	this	article.)
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target	of	these	two	miRNAs,	that	are	described	as	negative	regulators	of	cell	death	induced	by	cell	detachment	(anoikis)	in	tumor	cell	lines	model.	miR-30b	and	miR-30c	seem	able	to	block	anoikis,	by	inhibiting	caspase3	(Moreno-
Mateos	et	al.,	2013).	Therefore,	miR-30	downregulation	after	SCI	may	contribute	to	the	exacerbation	of	secondary	SCI.
Also	miR-223	and	miR-384-5p	can	act	on	caspase	3:	miR-223	is	expressed	at	high	levels	at	different	time	points	(1,	3,	7	and	14	days)	after	SCI	and	its	inhibition	significantly	improved	rat	motor	recovery	with	a	decrease	in	cell
apoptosis.	Similarly,	the	cleaved	caspase3	is	 indirectly	upregulated	by	miR-384-5p	in	a	hypoxic	cell	 line	model	(Bao	et	al.,	2013):	considering	the	inhibitory	general	role	of	miRNAs,	 in	both	cases,	they	probably	act	on	an	unknown
factor/molecule	(question	mark	in	Fig.	4)	that	in	turn	activates	caspase3.	The	involvement	of	these	two	miRNAs	in	the	apoptotic	pathway	is	straightforward	but	need	to	be	clarified	in	order	to	be	exploited	for	therapeutic	purposes.
11	MYELINATION-RELATED	MIRNAs	FOLLOWING	CNS	and	PNS	LESIONyelination-related	MIRNAs	following	CNS	and
PNS	lesion
Myelination	 is	a	 finely-tuned	process	essential	 for	both	 the	normal	development	of	CNS/PNS	and	repear	after	an	 injury:	 indeed	some	of	 the	mechanisms	described	during	development	 (see	below)	can	be	recapitulated	 in
response	 to	 a	 trauma	 (McTigue	 and	 Tripathi,	 2008)	 as	 schematized	 in	 Table	 1.	 According	 to	 a	 well-defined	 spatiotemporal	 differentiation	 cascade,	 undifferentiated	 OPCs	 and	 Schwann	 progenitor	 cells	 (SPCs),	 in	 CNS	 and	 PNS
respectively)	can	give	raise	to	mature	OLs	and	SCs,	responsible	for	axonal	myelination.	The	balance	between	promoting	and	inhibiting	factors	precisely	orchestrates	such	differentiation.	miRNAs	play	a	critical	role	in	regulating	the
production	and	differentiation	of	both	myelinating	cells	and	in	maintaining	their	identity	(He	et	al.,	2012),	as	demonstrated	by	the	selective	depletion	of	Dicer	in	OLs	and	SCs:	indeed	postnatal	OL-specific	Dicer-floxed	mice	present	an
increased	demyelination	combined	with	inflammatory	astrocytosis	and	microgliosis,	oxidative	damage	and	neuronal	degeneration	(Shin	et	al.,	2009).	Similarly,	Dicer	deletion	from	mouse	SCs	prevents	the	formation	of	a	mature	myelin
sheath	(Pereira	et	al.,	2010;	Yun	et	al.,	2010).	Moreover,	miRNAs	can	induce	the	switch	from	neurogenesis	to	gliogenesis	during	spinal	cord	development,	as	OL	transcription	factor	1-Dicer	KO	mice	completely	lack	oligodendrogenesis
and	astrogliogenesis	in	the	ventral	neuroepithelial	cells	(Zheng	et	al.,	2010).	In	literature	the	list	of	myelination-related	miRNAs	is	quite	long	(Bremer	et	al.,	2011;	Dugas	and	Notterpek,	2011;	He	et	al.,	2012;	Lau	et	al.,	2008;	Yun	et	al.,
2010)	although	only	some	of	them	appear	to	be	crucial	to	complete	the	myelination	process.	Furthermore,	despite	the	distinct	CNS	and	PNS	pathways	(Svaren,	2014),	some	of	these	main	myelination-related	miRNAs	(miR-9,	miR-138
and	miR-338)	can	be	detected	in	both	systems.	For	example,	miR-9	is	involved	both	in	OPC	and	SPC	maturation	acting	on	the	same	target,	i.e.	PMP-22	predominantly	expressed	in	SCs.	However,	while	in	the	CNS	PMP-22	expression	is
inhibited	by	high	miR-9	levels	in	vitro,	in	the	PNS	PMP-22	expression	is	not	affected	by	low	miR-9	levels	(Lau	et	al.,	2008;	Verrier	et	al.,	2009).	Similarly,	miR-219,	miR-138	and	miR-338	can	regulate	OL	or	SC	maturation	respectively	in
the	CNS	and	the	PNS.	 In	 the	CNS,	 these	miRNAs	have	been	 identified	by	qRT-PCR	as	the	three	main	small	RNAs	 in	differentiating	OLs	with	an	 increase	 fold	change	of	100,	30	and	30	respectively.	Even	though	miR-219	alone	 is
necessary	and	sufficient	to	promote	OL	differentiation,	all	three	miRNAs	are	involved	in	different	stages	of	this	process.	miR-219	directly	inhibits	OPC	proliferation	factors,	such	as	platelet-derived	growth	factor	α,	Sox6,	hes	family
bHLH	transcription	factor	5	(Hes5),	zinc	finger	protein	238	(ZFP238),	forkhead	box	J3	(FoxJ3)	and	platelet	derived	growth	factor	receptor	α	(PDGFRα)	and	its	overexpression	is	also	able	to	induce	OPC	differentiation	by	inhibiting	the
same	targets	(Dugas	et	al.,	2010;	Zhao	et	al.,	2010b).	Sox6,	Hes5	and	ZFP238	are	also	targeted	by	miR-338	that,	in	addition,	is	predicted	to	inhibit	fibroblast	growth	factor	receptor	2	(FGFR2,	an	OPC	mitogen	receptor).	Some	pro-
neurogenic	factors,	such	as	NeuroD1,	Isl1	and	Otx2,	are	presumably	inhibited	by	miR-338	and	miR-219,	thus	conferring	to	these	miRNAs	multiple	roles	in	OL	differentiation	(Dugas	et	al.,	2010;	Zhao	et	al.,	2010b).	miR-138	is	described
to	extend	the	early	stages	of	OL	differentiation	(so	that	the	cells	can	produce	mature	myelin	sheath),	likely	acting	on	Sox4,	which,	in	combination	with	Sox6,	inhibits	the	process.	As	previously	stated,	these	three	miRNAs	are	also	key
players	during	SC	differentiation	albeit	targeting	different	molecules.	miR-138	represses	three	genes	usually	expressed	in	undifferentiated	SCs,	cyclinD1,	Sox2	and	Jun	(Yun	et	al.,	2010).	On	the	other	hand	miR-338	expression	is	under
the	control	of	Sox10,	a	transcription	factor	that	control	OL	and	SC	differentiation,	indicating	that	this	miRNA	may	play	a	role	in	peripheral	myelination	even	though	its	targets	are	not	clearly	identified	(Gokey	et	al.,	2012;	Yun	et	al.,
2010).	Therefore,	these	miRNAs	are	shared	between	CNS	and	PNS,	but	they	maintain	different	mechanisms	of	action.	Considering	the	pivotal	role	of	miRNAs	during	myelin	formation/maintenance	in	CNS	and	PNS,	one	can	foresee
their	 involvement	 in	disease	and	 injury.	 Indeed	miRNAs	can	act	 in	demyelinating	diseases	 such	as	multiple	 sclerosis,	 leukodystrophy,	 ischemic	 stroke,	peripheral	nerve	 injury	and	SCI.	After	SCI,	OLs	undergo	acute	necrosis	 and
apoptosis	with	a	progressive	reduction	in	cell	number	until	3	weeks	after	injury	(Crowe	et	al.,	1997).	The	demyelination	occurring	after	the	trauma	is	partially	counteracted	by	a	spontaneous	remyelination	generally	starting	2	weeks
post	injury	(Harrison	and	McDonald,	1977).	OPCs	are	responsible	for	this:	the	reactivation	of	developmental	factors	induce	their	proliferation	and	migration	into	the	lesion	area	(Almad	et	al.,	2011).	On	the	contrary,	SCs	react	more
robustly	to	a	peripheral	nerve	injury	compared	to	OLs	in	the	CNS:	as	the	wallerian	degeneration	(i.e.	the	degeneration	of	the	distal	axon)	takes	place,	distally	to	the	lesion	SCs	start	to	dedifferentiate,	remove	the	myelin	debris	and
recruit	macrophages	for	further	clearing	the	damaged	area.	Several	molecular	pathways	are	activated	during	this	process,	finally	leading	to	a	regained	contact	between	axons	and	dedifferentiated	SCs	that	can	now	differentiate	into
mature	myelinating	cells	 (Glenn	and	Talbot,	2013).	How	miRNAs	 contribute	 to	myelin	 destruction/formation	 in	CNS/PNS	 is	 not	 completely	 understood.	 It	 has	 been	 demonstrated	 that	 the	 same	miRNAs	 implicated	 in	OL	 and	SC
maturation	during	development	can	switch	their	expression	after	SCI	and/or	peripheral	nerve	injury,	although	their	role	remain	debated	in	these	conditions:	at	least	two	of	the	main	miRNAs	previously	described	(miR-9	and	miR-219,
together	with	miR-384-5p)	seem	to	be	promising	circulating	biomarkers	for	evaluating	the	severity	of	SCI,	since	their	concentration	in	the	murine	serum	is	strongly	upregulated	12	h	after	the	injury	(3	h	and	24	h	in	the	case	of	miR-9)
(Hachisuka	et	al.,	2014).	Moreover	miR-219	(and	in	particular	its	form	miR-219-2-3p)	and	miR-338	are	downregulated	after	contusive	SCI	(Liu	et	al.,	2009;	Zhao	et	al.,	2010b).	Although	a	specific	role	for	many	of	these	miRNAs	after
SCI	has	not	been	identified,	it	is	likely	they	are	needed	at	different	time	points	after	the	lesion	to	reestablish	the	OL	population	both	by	increasing	OPC	proliferation	and	by	promoting	OL	differentiation.	As	a	consequence	of	their
redundant	 function,	 some	miRNAs	may	 concurrently	 influence	different	biological	 processes.	For	 example	miR-9,	 previously	described	as	 involved	 in	 the	axon	growth	 (Fig.	3)	 and	 inflammatory	 networks	 (Fig.	 4),	 could	 be	 also	 a
regulator	of	myelination:	the	study	of	Zhou	S	and	coll.	described	miR-9	downregulation	after	rat	sciatic	nerve	transection	as	an	important	mechanism	to	allow	SC	migration	in	a	regenerative	attempt	(Zhou	et	al.,	2014).	Also	miR-138	(a
key	regulator	of	OL	development)	has	been	associated	to	SCI:	however	in	this	case	it	has	been	only	described	to	promote	neuroplasticity	through	vimentin	repression	in	vitro	(Fitzpatrick	et	al.,	2015;	Qian	et	al.,	2015).	The	connection
among	SCI,	miRNAs	and	myelin	regulation	remains	unclear	as	demonstrated	by	several	examples.	In	addition	to	miR-138,	other	eight	miRNAs	(miR-146a,	miR-181a,	miR-145,	miR-17,	miR-148b-3p,	miR-1,	miR-221	and	miR-222)	have
been	related	to	OL	or	SC	maturation,	but	they	are	also	differentially	involved	after	SCI	with	distinct	and	additional	functions.	For	example,	miR-146a,	in	addition	to	its	anti-inflammatory	capabilities	(Fig.	4)	(Yunta	et	al.,	2012),	also
plays	a	role	 in	 the	regulation	of	OPCs/OLs	after	a	 lesion,	as	 it	has	been	proposed	as	a	possible	oligodendrogenesis	 inducing	 factor	after	middle	cerebral	artery	occlusion	 (MCAo).	Moreover,	 in	vitro	 it	 is	able	 to	promote	neuronal
progenitor	cell	(NPC)	differentiation	into	O4-positive	OPCs	(targeting	IRAK1	and	thus	increasing	the	expression	of	myelin	proteins)	(Liu	et	al.,	2016).	A	role	for	miR-146a	in	myelination	can	be	also	hypothesized,	since	it	can	push	OLs	to
differentiate	when	activated	by	thymosin	β4	acting	on	IRAK1	and	TRAF6	(Santra	et	al.,	2014).	Another	interesting	example	comes	from	miR-181a:	in	a	contusive	SCI	model,	it	participates	to	the	inflammation	process,	as	previously
described	(Fig.	4),	being	downregulated	7	days	post	injury	(Liu	et	al.,	2009).	This	miRNA	is	generally	classified	as	a	tumor	suppressor	in	gliomas,	but	it	can	also	stop	OPC	proliferation	and	start	OL	differentiation	in	vitro	(Dugas	et	al.,
2010).	Similarly,	miR-145	(together	with	miR-199a-5p)	is	a	regulator	of	myelin	regulatory	factor	(C11Orf9),	the	human	analog	of	myelin	regulatory	factor	(MRF),	one	of	the	mouse	protein	necessary	for	OL	maturation	(Letzen	et	al.,
2010).	As	for	miR-146a,	also	its	expression	is	altered	after	SCI,	but	miR-145	acts	on	different	pathways:	indeed	the	contusion	SCI	can	upregulate	miR-145,	whose	potential	targets	are	anti-apoptotic	genes,	such	as	the	Bcl-2	(Liu	et	al.,
2009).	Another	miRNA	upregulated	after	a	spinal	contusive	lesion	and	involved	in	the	control	of	OL	number	is	miR-17	(Liu	et	al.,	2009).	This	small	RNA	is	a	member	of	the	miR-17-92	cluster,	previously	described	in	PTEN	pathway	(Fig.
2):	their	lack	causes	the	reduction	in	myelinating	cell	number	in	vivo,	while	their	expression	promotes	OPC	proliferation	by	AKT	signal	(Budde	et	al.,	2010).	Other	interesting	examples	consist	in	miR-148b-3p	and	miR-1	(Liu	et	al.,
2009;	Yunta	et	al.,	2012).	The	first	is	downregulated	after	SCI	with	an	anti-apoptotic	function,	while	the	second	is	upregulated	after	SCI	with	a	pro-inflammatory	and	apoptotic	function.	Moreover,	they	are	both	described	as	miRNAs
regulating	in	vitro	proliferation	and	migration	of	SCs	acting	directly	on	cullin-associated	and	neddylation-dissociated	1	(CAND1-miR-148b-3p)	and	BDNF	(miR-1)	(Qian	et	al.,	2016;	Yi	et	al.,	2016).	More	in	detail,	miR-1	is	a	negative
regulator	of	BDNF	that	results	downregulated	after	peripheral	nerve	injury	thus	reflecting	the	high	BDNF	level	detected.	Differently,	miR-221	(upregulated	after	SCI	and	enriched	in	sympathetic	neurons)	and	miR-222	can	promote	SC
proliferation	and	migration	in	vitro	as	demonstrated	by	LASS2	repression	after	sciatic	nerve	injury	(Liu	et	al.,	2009;	Natera-Naranjo	et	al.,	2010;	Yu	et	al.,	2012b).	Another	set	of	miRNAs	(miR-145,	miR-338	and	miR-138)	have	been
specifically	related	to	SC	development	and	play	a	major	role	after	PNS	injury.	miR-145,	also	described	in	CNS,	has	been	correlated	to	the	defined	“injury	response	gene	cluster”	by	Chang	et	al.	(2013)	but	it	was	previously	related	to	SC
postnatal	development	(Verrier	et	al.,	2010).	miR-338	(myelination-related	miRNA	during	development)	 is	one	of	22	miRNAs	potentially	 linked	to	nerve	regeneration,	as	suggested	by	a	recent	miRNA	sequencing	profile	study	after
sciatic	nerve	injury:	this	miRNA	targets	ADAM17,	a	protein	which	seems	essential	for	CNS	myelination	(Palazuelos	et	al.,	2014;	Yu	et	al.,	2011a).	miR-338	role	in	peripheral	injury	is	also	demonstrated	in	vivo	by	its	therapeutic	efficacy,
when	 transfected	 in	 combination	with	miR-21,	 after	 sciatic	nerve	 injury.	When	 the	 injured	animals	 are	 treated	with	 these	 two	miRNAs,	 8	weeks	after	 surgery,	 axon	diameter	 and	myelin	 thickness	 increase,	 assuring	a	 significant
functional	recovery	compared	to	the	sham	group	(Wang	et	al.,	2016a).	Concerning	miR-138,	interestingly	during	development	it	represses	anti-myelinating	factors	such	as	Sox2	and	c-Jun	to	promote	myelin	formation.	However,	after	a
PNS	injury	its	downregulation	activates	a	regenerative	response	to	allow	early	growth	response	2	(Egr2)	(one	of	miR-138	target)	exert	its	role	as	pro-myelinating	factor	in	vivo	(Adilakshmi	et	al.,	2012).	Finally	two	miRNAs	upregulated
after	nerve	injury,	miR-132	and	miR-182,	play	opposite	roles	on	SC	proliferation	and	migration.	While	the	increased	expression	of	miR-132	promotes	in	vitro	SC	migration	targeting	protein	kinase	AMP-activated	non-catalytic	subunit
gamma	3	(PRKAG3)	gene	and	thus	facilitating	the	regeneration	process,	miR-182	inhibits	the	same	processes	acting	on	fibroblast	growth	factor	9	(FGF9)	and	neurotrimin	(Yao	et	al.,	2016;	Yu	et	al.,	2012a).	In	conclusion,	a	complex
crosslink	involving	myelination-related	miRNAs	during	development	and	after	an	injury	is	evident	both	for	CNS	and	PNS.	Although	the	intertwined	connections	between	the	two	systems	are	poorly	understood,	investigating	the	role	of
miRNAs	related	to	myelination	will	help	to	fill	the	gaps	in	an	overall	framework.
Table	1	Myelination-related	miRNAs	in	CNS	and	PNS	in	physiological	and	pathological	conditions.	In	the	columns	CNS	and	PNS	injury	UP	and	DOWN	indicate	miRNA	expression	changes.
alt-text:	Table	1
Cell	type/	animal
model
CNS PNS CNS	target(S)) PNS
target(S))
Function(S)	in	CNS Function(S)	in
PNS
CNS	injury PNS	injury Other	implications
miR-9 OL,	SC	primary
culture
✓ ✓ PMP-22 PMP-22 inhibition	of	PNS
specific	molecules
compact	myelin
formation
UP	biomarker	for
SCI	severity
DOWN	SC	migration axon	growth	(Fig.	3)
Inflammation	(Fig.	4)
miR-219 OPC	primary	culture ✓ X PDGFRα,	Sox6,	Hes5,	ZFP238,
FoxJ3,	NeuroD1,	Isl1,	Otx2
X OL	differentiation X DOWN	Biomarker
for	SCI	severity
X X
miRR-338 OPC	primary	culture ✓ ✓ PDGFRα,	Sox6,	Hes5,	ZFP238,
NeuroD1,	Isl1,	Otx2,FGFR2
ADAM17 OL	differentiation likely
peripheral
myelination
DOWN
undetermined
UP	increased	axon	and
myelin	size;	recovery
X
miR-138 OPC	primary	culture, ✓ X Sox4,	vimentin,	Egr2 CYCLIN OL	differentiation SC UP	neuroplasticity DOWN	regenerative X
SC	Dicer1	KO	mice D1,	Sox2,
Jun
differentiation response
miR-146a OPC	primary	culture ✓ X IRAK1,	TRAF6 X from	NPC	to	O4-
OPCs;	OL
differentiation
X UP	OL	genesis
after	MCAo
X Inflammation	(Fig.	4)
miR-181a Induced	OLs ✓ ✓ undetermined X tumor	suppressor	in
glioma	cells
OL
differentiation
DOWN
undetermined
X Inflammation	(Fig.	4)
miR-145 Induced	OLs,	SC
Dicer1	KO
✓ X MRF X OL	maturation SC	maturation UP	undetermined X X
miR-17-92OL
miR-17-–92
OL	miR-17–92	KO
mice
✓ X AKT	signal X control	of	OL	number X UP	undetermined X axon	growth	(Fig.	2)
miR-132 SC	primary	culture ✓ ✓ X PRKAG3 X undetermined X UP	SC	migration X
miR-182 SC	primary	culture ✓ ✓ X FGF9,
neurotrimin
X undetermined X UP	Inhibition	of	SC
migration
X
miR-148b-3p SC	primary	culture ✓ ✓ undetermined CAND1 undetermined SC	proliferation
and	migration
DOWN	anti-
apoptotic	in	SCI
undetermined X
miR-1 SC	primary	culture ✓ ✓ undetermined BDNF undetermined SC	proliferation
and	migration
UP	pro-
inflammatory	and
apoptotic
DOWN	BDNF	increase X
miR-221 SC	primary	culture ✓ ✓ undetermined LASS2 undetermined undetermined UP	undetermined UP	SC	proliferation	and
migration
X
miR-222 SC	primary	culture ✓ ✓ undetermined LASS2 undetermined undetermined X UP	SC	proliferation	and
migration
axon	growth	(Fig.	2)
12	HOW	TO	MANIPULATEow	to	manipulate	miRNAs
The	pathways	above	mentioned	demonstrate	the	central	role	of	miRNAs	in	case	of	trauma	in	modulating	axonal	growth,	inflammation,	apoptosis	and	remyelination:	therefore	the	manipulation	of	their	expression	in	neurons	can
be	pivotal	i)	to	understand	their	role	in	neural	diseases	and	neuropathological	conditions	as	SCI;	ii)	to	exploit	their	therapeutic	potential.
The	best	way	to	study	the	physiological	functions	of	miRNAs	both	in	vitro	and	in	vivo	is	to	overexpress/downregulate	them	either	in	the	whole	organism	or	in	a	particular	cell	type.	Expression	in	neurons	can	be	modified	by
transfection,	transduction	of	miRNA	plasmid	or	miRNA	mimics/miRNA	antagonists.	However,	the	insertion	of	artificial	miRNAs	in	primary	culture	neurons	is	generally	toxic	and	poorly	efficient,	while	in	vivo	their	delivery	is	affected	by
their	 inefficient	uptake,	stability	and	regulation	of	expression.	miRNA	overexpression	may	elucidate	the	effect	of	 the	 inhibition	of	a	specific	protein	or	overcome	a	miRNA	downregulation.	 It	 is	obtained	by	administrating	plasmids
containing	a	specific	miRNA	gene	or	artificial	miRNA	mimics	delivered	by	viral	or	not	viral	vectors.	miRNA	mimics	are	synthetized	as	double-stranded	RNA	oligonucleotides	with	different	types	of	chemical	modification	that	make	them
suitable	miRNA	 substitutes	 both	 in	 vitro	 and	 in	 vivo.	 These	 formulations	 protect	miRNA	 oligonucleotides	 from	 enzyme	 degradation	making	 the	 cellular	 uptake	 efficient.	 The	 efficiency	 of	 plasmid/miRNA	mimics	 depends	 on	 the
transfection	technique.
12.1	TRANSFECTION	METHODSransfection	methods
The	most	common	approach	to	deliver	a	miRNA	plasmid/miRNA	mimic	into	the	cells	is	lipofection:	it	consists	in	embedding	the	miRNA	gene	plasmid	into	liposomes,	exploiting	the	capability	of	these	vesicles	to	fuse	with	the	cell
membrane.	Thus	lipofection	conjugates	the	anionic	charge	of	the	miRNA	with	a	mix	of	lipids	with	cationic	head	groups.	Lipofection	has	been	for	example	used	to	study	miR-485	overexpression	role	in	controlling	the	dendritic	spine
number	and	synapse	formation	in	hippocampal	neurons	culture	(Cohen	et	al.,	2011).	Moreover	an	in	vivo	approach,	by	tail	 injection	of	a	glycol-modified	 liposome,	was	equally	efficient	 in	delivering	miR-126	(promoting	angiogenesis
through	vascular	endothelial	growth	factor	inhibition)	to	the	thigh	muscles	of	an	ischemic	mouse	model	(Endo-Takahashi	et	al.,	2015).	Alternatively,	a	polymeric	delivery	system,	the	cationic	polymers	polyethylene	imine,	again	creates	a
good	cationic	shielding.	miRNA	plasmids/mimics	can	also	be	encapsulated	and	delivered	by	exosome	nanoparticles.	Exosome-mediated	transfer	of	miRNAs	is	a	mechanism	of	information	exchange	occurring	spontaneously	among	cells
(Valadi	et	al.,	2007).	For	example,	modified	exosomes	loaded	with	exogenous	siRNA	have	been	introduced	in	a	murine	brain,	leading	to	BACE	1	knockout	specifically	in	neurons	(Alvarez-Erviti	et	al.,	2011).	Moreover,	the	tail	injection	of
miR-124	rabies	virus	glycoprotein	(RVG)-modified	exosome	in	a	mouse	model	of	ischemic	stroke	limited	the	injury	spread	by	promoting	cortical	neurogenesis	(Yang	et	al.,	2017).	The	efficiency	achieved	by	the	packaging	and	the	cationic
charge	and	exosome	encapsulation	lead	in	both	cases	to	an	efficient	miRNA	delivery,	suggesting	liposomes	and	cationic	polymers	polyethyleneimine	as	promising	miRNA-based	therapeutic	strategies.
Although	no	clinical	trial	based	on	miRNA	transfection	is	today	available	for	the	treatment	of	CNS/PNS	disorders,	some	of	the	above	mentioned	transfection	methods	(by	liposomes,	nanoparticle	or	polyethyleneimine)	have
already	 found	 their	application	 in	cancer	 therapy:	 for	example,	miR-RX34	 intravenous	 liposome	 injection	and	miR-16	mimic	 (called	TargomiR)	have	both	successfully	completed	a	phase	 I	clinical	 trial	 for	primary	 liver	cancer	and
malignant	pleural	mesothelioma,	suggesting	their	viability	(www.clinicaltrials.gov).	This	probably	means	that	the	use	of	miRNAs	as	therapeutic	drugs	could	be	clinically	employed	also	in	the	neurological	field	in	the	near	future.
Another	highly	efficient	technique	in	neurons	is	magnetofection	that	consists	in	the	association	of	nucleic	acid	with	cationic	magnetic	nanoparticles	that	are	then	transported	into	the	cells	by	a	magnetic	field.	A	good	neuron
viability	and	a	high	transfection	rate	can	also	be	achieved	by	electroporation	and	nucleofection,	a	method	that	transfers	directly	the	substrate	into	the	cell	nucleus	and	the	cytoplasm	(Zeitelhofer	et	al.,	2007).	However	magnetofection,
electroporation	and	nucleofection	are	valid	techniques	for	in	vitro	miRNA	studies	before	cell	plating,	but	they	cannot	be	used	for	in	vivo	application.	All	these	delivery	systems	are	considered	stable,	non-immunogenic	and	suitable	for
specific	modifications	needed	to	reach	a	good	efficiency.
12.2	VIRUSESiruses
Viral	vectors,	such	as	adeno-associated	viruses	(AAVs),	lentiviruses	and	retroviruses,	can	reach	a	high	efficiency	expression	rate	in	neurons	conferring	in	vitro	and	in	vivo	other	type	of	properties.	AAVs	are	able	to	transduce	both
dividing	and	not	dividing	cells	with	the	main	advantage	to	produce	a	long	term	expression	of	the	transgene	located	in	its	genome.	Tissue-specific	tropism,	high	transduction	efficiency,	relatively	non	pathogenic	and	safety	make	these
viruses	ideal	as	miRNA	mimics	and	antagonist	transductors.	The	choice	among	about	12	AAV	serotypes	with	different	ways	of	administration	makes	possible	miRNA	manipulation	in	vivo.	For	example,	the	AAV9	encoding	an	artificial
miRNA	against	superoxide	dismutase	1	(SOD1)	protein	was	efficiently	injected	in	the	cerebral	ventricles	of	a	mouse	model	of	ALS	showing	its	therapeutic	effect	on	both	upper	and	lower	motor	neurons	(Stoica	et	al.,	2016).	Long	lasting
gene	expression	and	low	toxicity	can	also	be	achieved	by	recombinant	AAV	(rAAV):	they	are	less	dangerous	and	more	workable	compared	to	other	viruses,	as	demonstrated	by	cerebrospinal	fluid	injection	of	an	rAAV-artificial	miRNA
targeting	SOD1	in	an	ALS	murine	model	leading	to	KO	of	SOD1	protein	and	slowing	disease	progression	(Wang	et	al.,	2014).	Moreover	rAAV	vectors	are	able	to	easily	cross	the	BBB	and	efficiently	transduce	both	neurons	and	astrocytes:
for	instance	rAAV9	has	been	tested	in	vivo	for	the	treatment	of	spinal	bulbar	muscular	atrophy	with	good	results	in	terms	of	mouse	behaviour,	body	weight	and	survival	(Miyazaki	et	al.,	2012).
Also	lentiviral	(LV)	vectors	can	be	employed,	as	demonstrated	in	vitro	by	lentiviral-mediated	miR-92	overexpression	in	cerebellar	granule	neurons	(Barbato	et	al.,	2010).	Their	higher	efficiency	rate	makes	them	suitable	vectors
also	in	vivo:	for	example,	they	have	been	successfully	used	in	an	ischemic	mouse	brain	to	increase	the	progenitor	number	and	the	microvessel	density	(miR-210-LV);	(Zeng	et	al.,	2016)	and	in	a	mouse	model	of	brain	injury	to	exert	a
neuroprotective	role	(miR27a-LV;	Sun	et	al.,	2017).	However	LV	employment	needs	to	be	carefully	considered	because	of	ex	vivo	manipulation	and	the	risk	of	mutagenesis.
The	specificity	 in	 infecting	dividing	cells	makes	retroviruses	useful	 to	study	the	role	of	a	specific	miRNA	during	neurogenesis.	This	 is	 the	case	of	miR-137,	whose	overexpression	by	retroviruses	 in	dentate	gyrus	postnatal
neurons	allowed	to	define	the	miRNA	roles	in	the	inhibition	of	dendritic	morphogenesis,	maturation	and	spine	development	both	in	cultured	neurons	and	in	vivo	(Smrt	et	al.,	2010).	Nowadays	several	clinical	trials	using	AAVs,	rAAVs	and
LVs	are	ongoing	for	gene	therapy	of	cancer,	Parkinson’s	disease,	Alzheimer’s	disease	and	Spinal	muscular	atrophy	 (SMA),	demonstrating	 these	methods	as	safe	and	tolerable	also	 for	 future	miRNA	approaches.	However	although
viruses	can	mediate	an	high	miRNA-efficiency	delivery,	their	therapeutic	use	in	CNS	needs	to	be	carefully	considered	in	terms	of	immunogenicity	and	oncogenesis.	Indeed	innate	immune	response	in	mouse	brain	as	consequence	of
AAV	administration	has	been	already	reported	(Lowenstein	et	al.,	2007).	Moreover	the	cost	for	an	high-quality	and	−quantity	production	of	viral	vectors	further	limits	their	application.
On	the	contrary,	miRNA	loss	of	function	is	used	to	reveal	the	role	of	a	specific	miRNA/miRNA	cluster	with	several	possible	strategies.	One	tool	consists	in	total	or	conditional	(tissue-specific	deletion)	knockout	murine	lines
which	allow	to	 investigate	the	specific	role	of	a	single	miRNA	in	the	CNS.	Even	though	CNS	application	of	 this	 technique	can	be	found	in	the	 literature,	 the	knockout	of	a	single	miRNA	is	only	partially	efficient	due	to	 functional
redundancy	and	miRNA	cooperation.	Moreover	in	case	of	miRNA	cluster	(notably,	miRNAs	derive	from	the	same	gene	locus),	the	complete	deletion	of	the	locus	results	in	the	loss	of	function	of	different	miRNAs	thus	making	difficult	to
distinguish	which	is	the	miRNA	responsible	for	the	knockout	phenotype	(Ruberti	et	al.,	2012).
12.3	ANTISENSE	OLIGONUCLEOTIDESntisense	oligonucleotides	(ASOs)
Due	to	these	limitations,	other	strategies	have	been	developed,	such	as	ASOs	that	target	the	seed	region	of	the	mature	sequence	of	a	specific	miRNA	by	silencing	or	degrading	it.	Compared	to	a	complete	knockout,	ASOs	allow
to	perform	an	inhibition	limited	in	time	and	dependent	on	ASO	pharmacokinetics.	Different	types	of	ASOs	can	be	classified	depending	on	the	chemical	modifications:	unmodified	RNAs,	2′-O-Methyl	RNAs,	2′O-methoxyethyl	RNAs,	locked
nucleic	acid	(LNA)	and	phosphorothioate	RNAs.	The	first	miRNA	inhibitors	used	in	mammals	were	antagomirs	(Krützfeldt	et	al.,	2005),	a	member	of	2′-OMe	RNAs,	that	have	a	good	inhibition	effect	in	brain	when	delivered	locally	but	not
systemically	(Krützfeldt	et	al.,	2007).	For	example,	high	miR-223	levels	after	a	rat	spinal	cord	compression	were	suppressed	by	the	intrathecal	injection	of	the	antagomir-223,	inducing	functional	recovery	and	angiogenesis,	and	limiting
apoptosis	in	vivo	(Liu	et	al.,	2015a).	However,	antagomirs	must	be	delivered	in	high	doses	to	be	effective	and	they	are	generally	used	to	downregulate	specific	mRNAs	to	study	their	function.	Alternatively,	2′O-methoxyethyl	RNA	and	LNA
have	been	developed	as	more	 resistant	 to	many	endonucleases	with	 respect	 to	antagomirs.	For	example,	miR-210-LNA	has	been	used	 in	a	 rat	model	 of	 ischemic	brain	 injury,	providing	a	neuroprotective	effect	 even	4	h	 after	 its
intracerebroventricular	(ICV)	injection	(Ma	et	al.,	2016).
12.4	miRNA-MASKING	ASOs/SPONGESmasking	ASOs/sponges
Alternatively	miRNA	function	may	be	inhibited	by	interfering	with	the	miRNA-mRNA	interaction	using	the	“miRNA-masking”	ASOs.	Such	modified	oligonucleotides,	first	developed	by	Xiao	et	al.	(2007),	bind	to	the	3′	UTR	of	the
miRNA	target	instead	of	linking	directly	to	the	miRNA	seed	region	(Xiao	et	al.,	2007).	Similarly,	competitive	inhibitors	called	“miRNA	sponges”	have	been	developed	as	RNA	transcripts	containing	multiple	binding	sites	for	miRNA	seed
regions	(Ebert	et	al.,	2007).	They	can	be	delivered	by	vectors	transfected	into	the	cells,	thus	inhibiting	the	miRNA	function	(Brown	and	Naldini,	2009).	As	they	are	synthetized	with	several	binding	sites,	they	can	be	used	to	silence	even	an
entire	 family	 of	miRNAs.	Moreover,	 sponges	with	 the	RNA	polymerase	 II	 as	promoter	 linked	 to	 a	 fluorescent	 reporter	have	been	constructed	 in	 order	 to	detect	 and	quantify	 sponge-treated	 cells.	The	potential	 of	 this	 strategy	 is
demonstrated	by	its	application	in	several	cell	culture	and	in	vivo	experiments.	As	an	example,	the	plasmid	GFP	sponges	for	miR-9	family	have	been	electroporated	in	mouse	embryonic	stem	cells	in	vitro	to	generate	a	GFP-miR-9-sponge
mouse	line,	allowing	the	conditional	inactivation	of	the	entire	miRNA	family	in	a	spatiotemporal-controlled	way:	thus	showing	that	miR-9	family	is	essential	in	the	control	of	dendritic	growth	during	development	(Giusti	et	al.,	2014).	Even
if	the	design	of	a	miRNA	sponge	is	not	difficult	and	quite	fast,	the	efficacy	in	 inhibiting	miRNA	is	not	easy,	due	to	the	requirement	of	a	reporter	assay	to	validate	the	target	gene.	Moreover	 it	 is	difficult	to	establish	the	degree	of
inhibition	of	an	entire	miRNA	family.
A	variant	of	the	“miRNA	sponge”	tool	are	tough	decoy	RNAs,	which	obtained	a	long	term	suppression	over	1	month	in	mammalian	cells.	These	molecules	are	stem	loop	structures,	acting	again	as	competitive	inhibitors,	with
specific	miRNA	binding	sequences	located	in	the	middle	of	the	molecule	(Carè	et	al.,	2007;	Staton	et	al.,	2011).
miRNA	target	protectors	can	also	be	used	to	study	the	role	of	miRNA	in	regulating	a	specific	gene;	they	are	designed	to	bind	the	miRNA	target	site	on	the	gene	of	interest,	consequently	blocking	miRNA	action	on	its	target	as	it
was	firstly	demonstrated	 in	vivo	for	miR-430	family	and	TGF-β	(Choi	et	al.,	2007).	For	 instance	they	have	been	used	to	 first	demonstrate	that	miR-101	binds	at	 the	specific	242-–248	position	of	 the	amyloid	precursor	protein	3′	UTR
regulating	the	target	level	in	HELA	cell	culture	(Long	and	Lahiri,	2011).
In	conclusion,	different	strategies	are	now	available	for	miRNA	overexpression	or	inhibition,	although	all	the	approaches	display	both	advantages	and	limitations,	that	need	to	be	carefully	considered	before	their	application.	As
a	valid	alternative	to	miRNA	use,	currently	the	most	common	therapeutic	strategy	to	inhibit	a	specific	mRNA	is	RNA	interference	technique	by	siRNA.	siRNA	are	21-nucleotides	double	stranded	RNA	molecules	discovered	to	be	potent
gene	expression	inhibitors	(Fire	et	al.,	1998).	Due	to	their	specificity,	siRNA	technology	is	widely	employed	in	the	study	of	nervous	system	diseases.	However	siRNAs	also	show	some	limitations,	due	to	their	 instability,	poor	cellular
uptake,	 inability	 to	 cross	 the	BBB,	 and	 immunogenicity	 (Gomes	 et	 al.,	 2015).	 To	 overcome	 these	 limitations	 several	 strategies	 have	 been	 proposed:	 the	 best	 results	 in	 terms	 of	 stability	 and	 permeability	 are	 reached	 by	 chemical
conjugation	and	stabilization	with	functional	molecules,	while	their	cellular	specificity	is	improved	by	nanoparticles	(NPs)	based	system	(such	as	RVG	peptides,	chitosan	or	lipid	NPs).	The	potential	of	siRNA	strategy	in	CNS-PNS	is
demonstrated	by	the	numerous	in	vivo	studies:	for	example,	a	specific	PUMA	siRNA	treatment	has	been	delivered	by	ICV	injection	in	subarachnoid	haemorrhage	rat	model	reducing	mortality	rate,	cerebral	oedema	and	neural	deficits
(Yan	et	al.,	2011).	Another	successful	example	of	functional	siRNA	modification	is	provided	by	Al-Jamal	et	al.	(2011):	in	this	study	a	carbon-nanotube	Caspase-3	siRNA	has	been	injected	directly	into	the	cerebral	cortex	of	ischemic	mice
reducing	neurodegeneration	and	promoting	functional	motor	recovery	(Al-Jamal	et	al.,	2011).	An	efficient	siRNA	delivery	is	also	reached	by	systemic	administration	as	demonstrated	by	a	polyethyleneimine	modified	claudin-5	siRNA,	able
to	reduce	oedema	and	cognitive	impairment	of	traumatic	brain	injury	mice	(Campbell	et	al.,	2012).	Moreover	another	valid	application	is	described	by	Alvarez-Erviti	et	al.	(2011)	that,	by	intravenously	injecting	RVG-β	secretase1	exosome
siRNA,	could	reduce	protein	expression	not	only	in	neurons	but	also	in	microglia	and	OLs.	Finally,	recently	the	intranasal	administration	of	microglia	cells	transfected	with	polyethyleneimine	modified	Beclin1	siRNA	has	been	found	in
the	cytoplasm	of	neurons	and	glial	cells	in	the	prefrontal	cortex	of	C57BL6/J	mice	4	h	and	24	h	post-delivery,	suggesting	this	method	as	a	not	invasive	technique	for	therapy	(Rodriguez	et	al.,	2017).
Thanks	to	the	encouraging	preclinical	results,	there	are	several	siRNA-based	protocols	 in	clinical	trials:	most	of	them	are	mainly	related	to	the	treatment	of	cancer	(Chakraborty	et	al.,	2017)	and	inflammatory	disorders	(for
example	the	siRNA	against	syk	kinase	gene	produced	by	Exccelair	company	and	used	for	the	treatment	of	asthma)	(Chakraborty	et	al.,	2017).	As	concerns	the	neurological	field,	it	is	noteworthy	that	13	siRNAs	for	ocular	diseases	are	now
in	clinical	trials:	 in	particular,	safety	and	preliminary	efficacy	tests	of	siRNA-027	and	Cand5	have	been	successfully	completed	for	the	treatment	of	macular	degeneration	by	intravitreal	 injections	(www.clinicaltrials.gov).	Moreover
intrathecal	infusion	of	two	antisense	oligonucleotides	(ISIS	333611	and	Nusinersen)	completed	phase	I	clinical	trial	for	the	treatment	of	ALS	and	SMA	respectively	(Chiriboga	et	al.,	2016;	Miller	et	al.,	2013).
In	 conclusion,	 considering	 the	 advances	 and	promising	 results	 obtained	 in	 the	 above	mentioned	examples,	we	 can	 speculate	 that	 the	use	 of	miRNAs	and/or	 siRNAs	 in	 the	 clinical	 application	 for	 the	 therapy	of	CNS/PNS
traumatic	disorders	could	be	not	so	far.
13	CONCLUSION	REMARKS:	miRNA	COOPERATION	AND	CONVERGENCEonclusion	remarks:	miRNA	cooperation	and
convergence
SCI	 is	 a	 complex	 sequence	 of	 events	 that	 interact	 among	 each	 other	 producing	 the	 devastating	 conditions	 that	 affect	 millions	 of	 people:	 indeed,	 after	 a	 trauma,	 several	 biological	 processes	 (e.g.,	 axonal
degeneration/regeneration,	inflammation,	cell	death,	myelin	loss),	apparently	independent,	are	actually	intertwined.	In	this	scenario,	miRNAs	work	as	a	perfectly	coordinated	network	in	which	every	element	is	just	a	part	of	the	whole.
Here	 the	complexity	of	 the	 system	has	been	 illustrated	 in	 some	molecular	pathways	 (Figs.	2–5),	where	every	 single	miRNA	can	act	 on	different	mRNAs	as	well	 as	 a	 single	molecule	 can	be	 targeted	by	 several	miRNAs.	As	 inner
regulatory	system,	miRNAs	achieve	a	precise	control	of	different	nervous	processes	coordinating	their	actions	to	orchestrate	a	complex	gene	expression	network.	Such	a	complicated	overview	of	the	miRNA	system	comes	from	the
demonstration	that	the	repression	exerted	by	one	single	miRNA	is	not	sufficient	to	influence	an	entire	biological	pathway,	as	already	showed	in	neocortical	development	studies	(Baek	et	al.,	2008;	Barca-Mayo	and	De	Pietri	Tonelli,
2014;	Selbach	et	al.,	2008).	Two	main	 theories	have	been	proposed	to	explain	how	miRNAs	can	manage	simultaneously	a	precise	control	of	several	processes.	The	 first	one	 is	based	on	the	“cooperation	hypothesis”:	 according	 to
Schouten	et	al.	(2013),	the	cooperativity	theory	refers	to	a	potentiation	of	the	translational	repression	achieved	by	the	interaction	of	different	miRNAs	on	multiple	seed	regions	on	the	same	mRNA	3′	UTR	(Schouten	et	al.,	2013).	The
pathways	proposed	in	the	present	review	well	fit	with	this	concept	and	explain	why	the	manipulation	of	one	single	miRNA	may	result	in	no	effect	due	to	the	compensation	exerted	by	the	other	miRNAs	binding	the	same	target.	During
the	last	years,	another	theory	emerged	referring	to	the	“convergent	miRNA	action”.	miRNA	convergence	is	defined	as	“the	synergic	action	of	one	or	more	individual	miRNAs	that	by	acting	on	different	seed	regions	in	one	or	more
target	genes	result	in	a	regulatory	effect”	(Barca-Mayo	and	De	Pietri	Tonelli,	2014).	More	in	detail,	the	authors	recognize	three	kinds	of	convergence:	“on	target”,	when	two	or	more	miRNAs	act	on	the	same	molecule;	“on	pathway”,
when	miRNA(s)	can	target	different	molecules	belonging	to	 the	same	pathway;	“on	function”,	when	one	or	more	miRNAs	act	on	different	elements	of	different	pathways	 that	share	 the	same	biological	 function.	All	 these	 types	of
convergence	can	be	also	found	in	the	pathways	described	above,	even	though	generally	every	miRNA	presented	here	has	been	studied	individually	for	its	specific	effect	in	PNS/CNS.	Therefore	the	“convergent	theory”	integrates	the
“cooperation	concept”,	contributing	to	render	miRNA	functioning	even	more	complicated.	Some	examples	of	convergent	miRNA	actions	in	the	CNS	have	been	already	described	in	cortical	development	studies,	including	i)	the	control
of	proliferation	and	commitment	of	neural	stem	cells/NPCs;	ii)	the	balance	between	survival	and	differentiation	of	cortical	progenitors;	iii)	the	specification	of	cortical	cell	subtypes	and	the	control	of	neurite	outgrowth;	iv)	the	migration
of	the	glutamatergic	cortical	neurons	(Barca-Mayo	and	De	Pietri	Tonelli,	2014).	Based	on	the	literature,	in	the	present	review	we	reported	some	examples	of	miRNA	convergence,	gathering	different	data	(experimentally	demonstrated
or	simply	hypothesized)	and	showing	how	the	miRNA	synergistic	effect	can	result	in	a	functional	outcome.	Actually	some	reports	tried	to	define	and	exploit	the	possible	synergic	effect	of	several	miRNAs	acting	on	the	same	pathway:
for	istance,	miR-20a	and	miR-128	are	an	example	of	“convergence	on	target”,	since,	repressing	PDZ-RhoGEF,	they	can	promote	the	neurite	growth	of	E17	cortical	neurons	in	vitro	((Sun	et	al.,	2013)	Fig.	2).	Even	more	representative,	is
the	“convergence	on	pathway”	of	miR-21	and	miR-199a-3p	in	SCI	as	mediators	of	synaptic	plasticity:	in	this	case	the	elevated	expression	of	miR-21	and	the	decreased	expression	of	miR-199a-3p	(induced	by	animal	exercise	after	injury)
well	correlate	with	PTEN	repression	and	mTOR	enhancement	respectively	((Liu	et	al.,	2012)	Fig.	1).	A	synergistic	effect	is	also	described	for	miR-20a	and	miR-29b	in	controlling	the	apoptotic	process	in	SCI:	in	vitro	their	combination
contributes	to	the	repression	of	the	anti-apoptotic	myeloid	cell	leukemia	sequence-1	(miR-20a	upregulation)	and	increases	the	levels	of	some	apoptosis	promoters	like	Bad,	Bim,	Noxa	and	Puma	(miR-29b	downregulation).	The	in	vitro
data	are	supported	by	the	proof	that	in	vivo	miR-20a	inhibitor	and	miR-29b	mimic	injections	decrease	the	level	of	caspase-3	in	a	cooperative	way	(Liu	et	al.,	2015b).	Another	recent	example	of	cooperative	action	on	the	same	function
comes	from	an	in	vitro	study	on	NSCs:	three	miRNAs	(miR-124,	miR-138	and	miR-137)	cooperatively	drive	differentiation	acting	on	a	set	of	genes	connected	in	a	network	of	TFs	with	Sp1	as	the	major	node	(Santos	et	al.,	2016).
The	convergent/combinatorial	concept	can	also	explain	the	synergistic	effect	of	two	or	more	miRNAs	compared	to	their	individual	efficacy.	As	previously	reported,	miR-9	and	miR-124	demonstrated	to	have	a	stronger	effect	in
promoting	dendritic	branching	of	differentiated	neurons	(in	vitro	NSC)	when	acting	together	instead	of	exerting	their	role	alone	(Xue	et	al.,	2016).	Also	miR-23a	and	miR-125b	are	individually	able	to	decrease	musashi	1	expression
level	(a	protein	involved	in	neuronal	progenitor	proliferation)	in	neuronal	stem/progenitor	cells,	but	their	synergistic	activity	produces	a	stronger	effect	(Gioia	et	al.,	2014).	Very	recently	a	group	of	11	miRNAs	has	been	identified	to
synergistically	control	the	fate	of	adult	hippocampal	neural	stem	cells	in	in	vitro	(adult	NSCs)	and	in	vivo	Dicer	KO	model	(Pons-Espinal	et	al.,	2017).	Another	example	comes	from	PNS	injury.	The	transfection	of	miR-338	and	miR-21	8
weeks	after	a	sciatic	nerve	lesion	promotes	a	functional	recovery	in	terms	of	sciatic	nerve	injury,	electrophysiological	analysis,	axon	diameter,	myelin	sheath	thickness,	G-ratio	and	ratio	of	wet	weight	of	the	gastrocnemious	muscle
(Wang	et	al.,	2016a).	Due	to	the	still	 little	number	of	miRNA	synergy	examples	 in	the	nervous	system,	we	cite	some	references	coming	from	other	domains,	where	the	concept	of	“synergy”	has	already	emerged.	For	example,	 the
treatment	of	non-small	cell	lung	cancer	with	the	combination	of	let-7b	and	miR-34a	overcomes	the	anti-proliferative	effect	obtained	by	individual	miRNA	administration	(Stahlhut	and	Slack,	2015).	Similarly,	only	the	combination	of	miR-
499	and	miR133	is	able	to	significantly	increase	the	expression	of	two	cardiac	specific	genes,	revealing	their	synergistic	effect	on	cardiac	differentiation	in	vitro	(Pisano	et	al.,	2015).	Even	if	combinatorial	approaches	are	now	emerging
as	new	way	to	study	miRNA	function,	the	full	description	of	miRNA	networks	remains	a	big	challenge.	The	reason	for	this	complexity	derives	both	from	the	miRNA	redundant	structure	and	from	our	lack	of	knowledge:	indeed,	although
about	2000	mature	miRNAs	have	been	sequenced	in	humans,	we	are	probably	still	far	from	the	total	number.	Every	year	new	miRNAs	are	annotated	in	the	main	database	(miRBase),	some	associated	with	validated	targets,	some	just
connected	with	predicted	targets	and	some	completely	unknown.	The	synergistic	strategy	adopted	by	miRNA	is	also	an	important	concept	for	several	diseases,	as	they	generally	involve	several	different	miRNAs	rather	than	one.	Indeed
computational	studies	demonstrated	that	miRNAs	in	complex	diseases	cooperate	and	act	on	genes	with	similar	functions,	thus	exploiting	a	synergism	in	function	even	more	significant	than	in	normal	cases	(Na	and	Kim,	2013;	Xu	et	al.,
2011).	In	this	sense	the	manipulation	of	one	single	miRNA	cannot	be	the	most	effective	therapeutic	strategy	for	SCI	or	CNS/PNS	pathologies,	but	nevertheless	allows	researchers	to	better	understand	miRNA	mechanisms	of	action	and
add	new	elements	to	the	miRNA	complex	networks.	In	conclusion,	a	global	view	is	necessary	to	understand	the	complexity	of	a	system	in	which	every	single	miRNA	operates	only	in	convergence	with	other	members.	This	is	still	a	new
and	underestimated	concept,	but	fundamental	to	understand	how	miRNAs	achieve	such	a	precise	coordinated	regulation.
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